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Summary 
 The induction of the adaptive and innate immune system is essential for controlling viral 
infections. Balance between the innate immune system and adaptive immune responses results in 
better antiviral immune activation. Not enough or too much activation can lead to impairment of 
immune responses. In this thesis, we have investigated the role of enforced viral replication and 
different mechanisms by which adequate innate and adaptive immune responses are generated. 
 Recently, it was shown that Usp18 dependent viral replication in splenic CD169+ 
macrophages are important to induce a sufficient type I interferon response resulting in the 
subsequent activation of adaptive immune responses. Here, in one study, we have shown that the 
intracellular replication of viral particles is sufficient to generate virus specific CD8 T cell 
responses. On the other hand, extracellular distribution of viral particles along the splenic 
conduits was necessary for inducing systemic levels of type I interferon (IFN-I). We have shown 
that Usp18 is important for viral replication, but that B cell-derived lymphotoxin beta is necessary 
for the extracellular distribution of virus along the marginal zone in spleen. 
 In a further study, we have demonstrated a role of CEACAM1 in B cell survival, 
proliferation and innate immune activation. B cells are important part of immune system because 
they are in close proximity of blood-borne antigen in splenic circulation, they secrete antibodies 
and maintain the lymphoid architecture. We have shown that cell intrinsic signalling of 
CEACAM1 is essential for survival of proliferating B cells. CEACAM1 is involved in B-cell 
receptor and signals through the Btk/Syk/NF-κB axis. Absence of CEACAM1 signalling leads to 
reduced number of B-cells in lymphoid organs especially marginal zone B cells and CD169+ 
macrophages. Absence of CEACAM1 leads to poor anti-viral antibody secretion after systemic 
infection with cytopathic virus resulting in early death of Ceacam1–/– mice. 
 In another set of experiment, we investigated the role of virus specific antibodies on 
adaptive immune activation. With the use of chronic virus strain LCMV-Docile, we determined 
whether enforced viral replication could occur in presence of virus-specific antibodies or virus-
specific CD8 T cells. We found that after systemic recall infection, virus-specific antibodies 
allow viral replication in splenic marginal zone but controlled in peripheral organs resulting in 
strong CD8 T cell priming whereas, virus-specific CD8 T cells blunted viral replication in spleen 
but failed to control the persistent chronic viral infection.  
 In conclusion, using several mouse models of noncytopathic and cytopathic viral 
infection, we have elucidated the functional role of lymphotoxin beta, CEACAM1 and virus-
specific antibodies in immune function particularly during enforced viral replication in the spleen.
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Zusammenfassung 
Die Aktivierung des adaptiven und angeborenen Immunsystems ist essentiell für die 
Kontrolle viraler Infektionen. Ausgeglichene Antworten des angeborenen und adaptiven 
Immunsystems führen zu einer verbesserten antiviraler Immunantwort. Zu geringe oder zu hohe 
Aktivierung führt zu einer verschlechterten Immunantwort. In dieser Arbeit wurde die Rolle der 
‘’enforced virus replication’’ und verschiedene Mechanismen untersucht, welche eine adäquate 
angeborene und adaptive Immunaktivierung garantieren.  
Kürzlich wurde gezeigt, dass die Usp18 abhängige Virusreplikation in splenischen 
CD169+ Makrophagen bedeutsam für eine hinreichende Typ I Interferonantwort ist, welche 
später zur Aktivierung der adaptiven Immunantwort führt. In dieser Arbeit wurde gezeigt, dass 
schon die intrazelluläre Replikation von Viruspartikeln genügte, um eine virusspezifische CD8 T 
Zell Antwort zu generieren. Des Weiteren wurde gezeigt, dass die extrazelluläre Verteilung 
viraler Partikel im gesamten Milzgewebe unabdingbar für die Induktion systemischer Level Typ 
I (IFN-I) war. Wir haben herausgestellt, dass Usp18 wichtig für die Virusreplikation ist, jedoch 
durch B Zellen produziertes Lymphotoxin beta notwendig für die extrazelluläre Verteilung von 
Virus entlang der splenisches Marginalzone ist.  
In einer weiteren Studie wurde die Rolle von CEACAM1 in Hinsicht auf das Überleben, 
die Proliferation und die angeborene Immunantikvierung von B Zellen untersucht. B Zellen sind 
ein wichtiger Bestandteil des Immunsystems, weil sie in direkter Umgebung der aus dem Blut 
stammenden Antigene in der splenischen Zirkulation sind; sie produzieren Antikörper und 
erhalten die lymphoide Struktur. Es wurde gezeigt, dass zellintrinsisches CEACAM1-signaling 
essenziell für das Überleben proliferierender B Zellen ist. CEACAM1 ist involviert in den B 
Zell-Rezeptor und interagiert durch den Btk/Syk/NF-κB Signalweg. Das Fehlen von CEACAM1-
signaling resultiert in einer reduzierten B Zellzahl in lymphoiden Organen, insbesondere von B 
Zellen und CD169+ Makrophagen in der Marginalzonen. Weiterhin führte die Abwesenheit von 
CEACAM1 zur einer mangelhaften antiviralen Antikörpersekretion nach systemischer Infektion 
mit zytopathischen Virus, was zu einem frühen Versterben der Ceacam1–/– Mäuse führte.  
Weitere Experimente untersuchten die Rolle virusspezifscher Antikörper auf die adaptive 
Immunaktivierung. Mit Hilfe des chronischen LCMV-Docile Virus wurde bestimmt, ob die 
‘’enforced virus replication’’ in der Anwesenheit von virusspezifischen Antikörpern oder 
Virusspezifischen CD8 T Zellen stattfinden kann. Es konnte gezeigt werden, dass nach 
wiederholter systemischer Infektion virusspezifische Antikörper die virale Replikation in der 
Marginalzone der Milz erlauben, wohingegen sie die Replikation in peripheren Organen 
kontrollierten. Obgleich dies zu einem starken T Zell priming führte, verminderten 
virusspezifische CD8 T Zellen die zwar die Virusreplikation in der Milz, scheiterten jedoch die 
persistierende virale Infektion zu kontrollieren.  
Zusammenfassend konnte auf mit Hilfe unterschiedlicher Mausmodelle, sowie nicht 
zytopathischer und zytopathischer viraler Infektion die Rolle von Lymphotoxin beta, CEACAM1 
und virusspezifscher Antikörper in Bezug auf die Immunfunktion, insbesondere ihrer Rolle in der 
‘’enforced virus replication’’ in der Milz, gezeigt werden.  
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1.1 Immune System 
The immune system has evolved to protect multicellular organisms from pathogens. It 
encompasses many biological processes and structures to protect host from invading 
pathogens such as viruses, bacteria, fungi, protozoa and worms.1 The immune system not 
only defends the host against external pathogens but also actively eliminates self-antigens as 
well as tumorigenic cells. Initially many researchers characterised the active immune 
components in the blood as having the ability to neutralize toxins. As those components were 
found in the serum (body component) it was called as “humoral immunity”. Other type of 
immunity generated by cellular response is called “cell-mediated immunity’’.2 T cells have 
an ability to recognise cells that are infected by pathogens and they have evolved 
mechanisms to distinguish between foreign and self-antigens called “tolerance”.2 There are 
two types of immune responses: innate and adaptive. Innate immunity is the first line of 
response and it is also known as the non-specific immune system whereas the adaptive 
immune system generates a specific response against pathogens. Adaptive immune system is 
an important part of the hosts’ defence as it results in long term memory formation.1 
      Minutes after Infection                 Days to Weeks after Infection 
Fig 1-1: Innate Versus Adaptive Immune System (Dranoff G., Nat. Rev. Cancer, 
2004, modified) 
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1.2 Types of Immunity 
1.2.1 Innate Immunity 
The innate immune system provides the first line of defence against infection and acts 
immediately after invasion by pathogens. The first line of defence includes the release of 
various soluble molecules in blood, antimicrobial enzymes such as lysozyme and 
antimicrobial peptides. Components of innate immune system don’t generate long lasting 
immunological memory. Epithelial surfaces of body comprise skin, gastrointestinal, 
urogenital and respiratory tracks provide the initial defence against pathogens. Epithelia is 
more than just a physical barrier as it produces a range of chemical substances such as 
digestive enzymes, bile acids and fatty acids in the gastrointestinal track. Lysozyme present 
in saliva and tears breaks the peptidoglycan component of bacterial cell wall is important for 
antibacterial defence.1, 3  
Apart from physical barriers two categories of lymphoid and myeloid lineages 
derived from the hematopoietic stem cells are precursors of the macrophages, granulocytes, 
dendritic cells and mast cells of the innate immune system.3 
 
 1.2.1.1  Macrophages 
Macrophages are the phagocytic cells that phagocyte and digest cellular debris, 
foreign particles, microbes and cancer cells. Macrophages reside in almost all tissues and can 
play several different roles. Some macrophages are involved in tissue regeneration and 
repair. Other macrophages which are stimulated by encounters with pathogens called 
inflammatory macrophages contribute to elimination of pathogens from a tissue and can act 
as antigen presenting cells (APC’s) that can activate T lymphocytes.1 
M1 macrophages are considered ‘’killer’’ macrophages and secrets high levels of 
IL(Interleukin)-12 upon activation by lipopolysaccharide (LPS) and IFN-γ. M2 macrophages 
are attributed a ‘’repair’’ function that involve in wound healing and tissue repair by 
secreting high levels of anti-inflammatory cytokine such as IL-10.4 Macrophages usually 
remain at strategic positions where the invasion is likely to occur. They are named according 
on the location in which they reside (Table 1-1).5 
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Anatomical Location Name 
Kupffer cells Liver 
Red pulp macrophages Spleen 
Alveolar macrophages Lung 
Monocytes Bone marrow 
Peritoneal Macrophages Peritoneal Cavity 
Sinus Histiocytes Lymph node 
Langerhans cells Skin 
  
Table 1-1: Different names of macrophages and their locations 
(Gordon S., et.al, Immunol. Rev., 2014, modified) 
 
Apart from red pulp macrophages there are specialized type of macrophages called 
metallophilic macrophages or marginal zone macrophages located in marginal zone of spleen 
or lymph nodes. They are characterized by the expression of CD169+ receptor and are 
important for viral replication and inducing adaptive immune responses.6,7 
 
 1.2.1.2 Granulocytes  
 Granulocytes are so named because of the dense granules in their cytoplasm and are 
of three types: basophils, eosinophils and neutrophils. These granules store proteins that are 
important for granulocytes to move to the site of infection and destroy the pathogen. At the 
time of infection mature basophils are released from bone marrow, travel to the site of 
infection and will release histamine, serine proteases and interleukins to initiate inflammatory 
response.8 Eosinophils are terminally differentiated effector cells involved in clearance of 
parasitic infections through the release of cytotoxic proteins.9 Neutrophils are not only the 
major pathogen fighting cells but also elicit immune responses against intracellular 
pathogens and viruses through complex cross talk with lymphocytes, dendritic cells and NK 
cells. The crosstalk is established by secreting lots of cytokines or by expressing several 
surface molecules.10 
 
 1.2.1.3 Dendritic Cells (DC’s) 
 DC’s are the most critical cells for the initiation of immune response arise from both 
myeloid and lymphoid lineage of hematopoietic cells.  DC’s are antigen presenting cells that 
are not only important for induction of primary immune responses but also immunological 
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tolerance. They help in establishing immunological memory by capturing antigen in tissues 
and presenting them to T cells in lymphoid organs.11 Lymphoid DC’s are localised in T cell 
rich areas in spleen and lymph nodes whereas myeloid DC’s are present in marginal zone of 
spleen. 
 DC’s can prime CD8 T cells in vivo and in vitro and strong antigen response can be 
elicited in vivo by presenting antigen bearing DC’s to T cells.12 CD11c expression on DC’s 
can lead to the generation of distinct T cell responses. CD11c+ DC’s can induce T cells to 
generate Th1 cytokines on the other hand CD11c  ̶   DC’s can induce T cells to generate Th2 
type cytokine response.13 At different stages of differentiation, DC’s can activate natural 
killer (NK) cells or NK T-cells11 through release of IL-12, IL-15 and IL-18.14 Other kind of 
DC’s called plasmacytoid dendritic cells (p-DC’s) which are mainly found in circulation and 
lymphoid organs are important players in secreting type I interferon (IFN-α/β) in response to 
viruses or viral peptides.15 
 
1.2.2 Adaptive Immunity 
 Adaptive immune system or acquired immune system is a specialized immune system 
that eliminates pathogens. All pathogens are not distinguished by innate immune system and 
when these pathogens escaped innate cells they are identified by a highly controlled process 
of adaptive immunity. Adaptive immunity mainly consists of 3 types of lymphocytes: B 
lymphocytes, T lymphocytes and NK cells.   
After antigen binding to a B cell receptor (BCR) on B cell surface, the lymphocytes 
will proliferate and differentiate in to plasma cells. B cells secret antibodies against specific 
antigen hence they can be targeted and eliminated by antibodies. On the other hand, unlike 
B-cells, T cell receptor (TCR) recognizes only processed pieces of antigens or peptides 
which are presented to them by protein molecules on the surface of APC’s called major 
histocompatibility complex (MHC) molecules. After antigen encounter, T cells are activated 
and proliferate. The hallmark of adaptive immune activation is the formation of memory and 
a more rapid response upon second encounter with the same pathogen.1, 3  
 
 1.2.2.1 B cells 
B cells are the main antibody secreting cells that generate and mature in the bone 
marrow. B-cells are found to secret large variety of cytokines and are major players of 
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adaptive immune responses. Due to number of functions of B cells, it’s important to study 
the factors affecting the development and function of B-cells. Therefore, in this study we 
investigated the development of B-cell and the role of B cells after the infection of cytopathic 
vesicular stomatitis virus (VSV). 
 
  1.2.2.1.a Development of B cells 
Bone marrow of mouse contains B lineage cells at each stage of development from 
progenitors to mature B cells. B cells are primarily divided in two groups B-1 and B-2 B-
cells. Murine B-1 cells are generated from fetal liver and are sustained in periphery by self-
renewal.16, 17 On the other hand, B-2 B cells are generated in bone marrow and are produced 
throughout lifelong (Table 1-2). 
 
 
 
 
 
 
 
 
 
 
 
Table 1-2: Overview of B-1 and B-2 B cells. (Naradikian MS., et.al, 2014) 
 
The expression of B cell receptor is fundamental to mature B-cell. Both B-1 and B-2 
cell lineage undergo V(D)J rearrangement. The V(D)J rearrangement provides the basis for 
classifying the development of B-2 cells in bone marrow (Table 1-3).  
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Table 1-3: Developmental stages of B-2 cells in bone marrow according to different 
research groups. (Naradikian MS., et.al, 2014) 
After reaching the immature stage, the developing B-2 cells will leave the bone 
marrow and will enter the circulation as transitional (TR) B cells. Transitional zone B cells 
are divided in three subsets T1, T2 and T3 before they develop in to follicular (FO) or 
marginal zone (MZ) B subset (Table 1-4). 
Location B cell subset Phenotype 
Bone marrow Newly formed, 
immature 
AA4+ CD23− sIgMhigh sIgD−/low HSAhigh CD62L− CD21/35−/low 
 T2-like AA4+ CD23+ sIgMhigh sIgDhigh HSAhigh CD62L+ CD21/35low 
 Mature CD23+ AA4− sIgMlow sIgDhigh HSAlow CD62L+ CD21/35low 
Spleen Transitional T1 CD23− AA4+ sIgMhigh sIgD−/low HSAhigh CD62L− CD21/35−/low 
 Transitional T2 CD23+ AA4+ sIgMhigh sIgDhigh HSAhigh CD62L+ CD21/35low 
 Transitional T3 CD23+ AA4+ sIgMlow sIgDhigh HSAhigh CD62L+ CD21/35low 
 Follicular type I CD23+ AA4− sIgMlow sIgDhigh HSAlow CD62L+ CD21/35int 
 Follicular type II CD23+ AA4−/low sIgMhigh sIgDhigh HSAlow CD62L+ CD21/35int 
 MZP CD23+ AA4−/low sIgMhigh CD1d+ sIgDhigh HSA+ CD21/35high 
 MZ CD23− AA4− sIgMhigh CD1d+ sIgDlow HSA+ CD21/35high 
Table 1-4: Cell surface markers for identification of bone marrow and splenic B cell sub-
populations. (Allman D., Pillai S., Curr Opin Immunol., 2008, modified) 
The fate of immature B-cell to develop into follicular or marginal depends on the 
extent of the BCR signal. Mouse studies have revealed that mature follicular zone B-cell 
numbers were increased as a result of increased BCR signal strength when a zinc finger 
protein Aiolos was knocked down.18 On the other hand, low or weak strength of BCR signal 
favours the development of marginal zone B cells.18 The mature B cells (IgDhigh) from spleen 
will leave in to circulation and travel back to the bone marrow. Various in vivo mouse studies 
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have proven that knocking out one or more functional protein in BCR signalling pathway 
leads to abnormal or no development of mature follicular or marginal zone B cells. 
 
  1.2.2.1.b Functional role of B cells   
B cells are not only antibody secreting cells but also serve many important functions 
in maintaining the structure of secondary lymphoid organs. In addition to antibody secretion, 
there are investigations showing that B cells are involved in antigen presentation, cytokine 
secretion and secretion of interleukin 10 (IL-10).19 B cell-deficient mice are also susceptible 
to autoimmune encephalomyelitis (EAE) highlighting the importance of B cells in 
autoimmune disease.20 Genaral B cell functions are summerised below (Fig. 1-2). 
  
 
 
 
 
 
 
 
 
Fig.1-2: Multifunction of B cells. (LeBien TW., Tedder TF., Blood, 2008) 
B cells are also required for the priming of CD4 T cells. In humans, abnormalities in 
B-cell development can lead to immunodeficiency’s like X-linked aggamaglobulinemia 
(XLA).21, 22 B-cell production of proinflammatory cytokines can also lead to autoimmunity 
by presentation of self-antigens to T cells.23 The splenic marginal zone separates white pulp 
from red pulp in the spleen. Due to the presence of marginal zone macrophages and marginal 
zone B cells in the white pulp area it plays an important role in up-taking blood born antigens 
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and gives the spleen antibacterial immunity. Follicular zone B-cells which are localized in 
follicles and the location of marginal zone B-cells around the white pulp are not only 
important for development but also for the maintenance of splenic marginal zone structure.24 
Marginal zone B-cells by their pre-activated state and location, joins B-1 B cells in the initial 
days of antigen response to generate massive IgM producing plasmablasts, providing a 
bridge between early innate and later adaptive immune responses.25 In addition to T-
independent responses, MZ B-cells can also participate in T-dependent responses to protein 
antigens by helping to deliver these antigens to follicular B cells. Furthermore, they may be 
activated by T-dependent antigens and receive T cell help.26 Also high levels of CD1d 
expression on MZ B-cells could lead to presentation of lipid antigens to NKT cells via the 
CD40-CD40 interactions giving rise to rapid class switched and somatically mutated 
antibody responses.27 In this study, we identified carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1) as being important for B cell development and 
maturation. Lack of CEACAM1 was linked to loss of marginal zone B cells in the spleen 
which resulted in less antigen presentation, antiviral antibody production and early death of 
Ceacam1–/–mice following cytopathic vesicular stomatitis virus (VSV) infection. 
  1.2.2.2 T cells 
T cells derive their name from their site of maturation the thymus. Like B-cells, T 
cells also express unique antigen binding receptor called the T-cell receptor (TCR). However, 
compared to B-cells which can detect soluble or particulate antigen by membrane bound 
antibodies, T-cells receptors recognize only processed antigens by APC’s bound to their 
MHC molecules.1 T cells are generally divided in two major types either T helper cell (TH) or 
T cytotoxic (TC) cell. Both cell types can be differentiated by presence of CD4 or CD8 
molecules on their surface respectively. CD4 T cells generally function as TH cells whereas 
CD8 T cells function as TC cells recognising antigen in complex with MHC-II and MHC-I 
respectively.1  
DC’s present antigenic peptides to naïve T cells in secondary lymphoid organs. 
Activated T cells rapidly expand and will migrate to the sites of antigen presence, and 
perform effector function such as cell mediated cytotoxicity and production of various 
cytokines. Cytotoxic CD8 T cells will directly lyse the infected cell containing the antigen, 
while CD4 T helper cells will produce cytokines which are cytolytic to target cells or 
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stimulate other T cell effector functions. CD4 T helper cells  can also activate B cell antibody 
production.28  
 
  1.2.2.2.a CD4 T cells 
Upon antigen activation CD4 T cells differentiate into different subsets namely Th1, 
Th2, Th9, Th17, Th22, Treg (regulatory T cells) and Tfh (follicular helper T cells), which 
secret distinct cytokines.29  
 
 
 
 
 
 
 
 
 
 
Fig. 1-3: Different CD4 subsets generated from naïve CD4 T cell by different cytokines and 
interleukins produced by them. (Golubovskaya V., Wu L., Cancers, 2016) 
 All CD4 T cell subsets are differentiated from naïve CD4 T cell by specific cytokines 
and each CD4 T cell subset secretes specific cytokines that have either pro- or anti-
inflammatory functions, survival or protective functions (Fig. 1-3).30  
 
  1.2.2.2.b CD8 T cells 
 CD8 T cells also called cytotoxic T lymphocytes (CTL’s), T-killer cells, killer T cells, 
destroy virus infected cells in acute and chronic viral infections.31 CD8 T cells can also 
infiltrate solid tumors such as primary melanoma32, ovarian cancers33, bladder cancer34, renal 
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cell carcinomas (RCC)35 and several other cancers.  CD8 T cells are also major players in the 
rejection of Graft in host transplant.36, 37 These cells recognize the target by binding to the 
antigen associated with MHC-I molecule on antigen presenting cells. After antigen challenge 
these cells differentiate into stem cell memory cells (TSCM), T central memory cell (TCM), T 
effector memory cell (TEM) and T effector cells (TEFF).
30 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4: Differentiation of CD8 T cell subset and different CD8 subsets.  
(Golubovskaya V., Wu L., Cancers, 2016) 
 
  1.2.2.2.c Memory T cells 
 Memory T cells are a subset of T cells that persist for a long time even after the 
infection has been cleared. Memory T cells expand quickly to generate a large number of 
effector T cells after re-infection with the same antigen. CD4 as well as CD8 T cells can form 
memory which are characterized by expression of CD45RO marker on their surface (Table 
1-5).38 Memory cells can be located in secondary lymphoid organs or recently infected 
tissues.30 Memory cells generally have several features: 1) Presence of previous expansion 
and activation, 2) persistence in the absence of antigen, 3) increased and quick activity upon 
re-exposure to antigen.39 
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  1.2.2.2.d Effector T cells 
 During primary immune response, T cells differentiate into effector cells in lymphoid 
organs. They must immediately home to peripheral tissue containing pathogen to generate 
inflammation by stimulating immune cells.40 Therefore, effector cells up-regulate the 
expression of receptors  for inflammation-induced endothelial adhesion molecules and 
inflammatory chemokines (Table 1-5).41 However, different pathogens can induce different 
effector responses generated by Th1 or Th2 cells. 
 Naïve Effector TEM TCM 
CCR7 +++ _ _ +++ 
CD62L +++ _ +/- +++ 
CD45RO + +++ +++ + 
CD45RA +++ _ + ++ 
CD95 +/- +++ ++ +/- 
Granzyme B _ +++ +/- _ 
CD25 _ + _ _ 
CD127 ++ +/- + +++ 
CD28 ++ _ + ++ 
Table 1-5: Phenotypic markers associated with naïve, effector and memory cells.  
(Nijkamp FP., Parnham MJ., Principles of Immunopharmacology, 2011, modified) 
 
1.3 Lymphotoxins 
 Lymphotoxin is a protein produced by Th1 T-cells which induces surface re-
arrangement of vascular endothelial cells to change the structure of cell adhesion molecules 
to recognise the pathogens by phagocytic cells. The lymphotoxin-α (LT-α) and tumor 
necrosis factor alpha (TNF-α) cytokines belongs to the TNF superfamily. Following the 
discovery of lymphotoxin-β (LT-β), it became apparent that these molecules form a 
heterodimer complex LTα1β2 which binds to a unique lymphotoxin-β receptor (LTβR).42 
Several remarkable immunological processes are carried out by lymphotoxins, including 
development of the lymph node, embryogenesis, generation and activation of dendritic cells 
(DC’s), and homeostatic control of chemokine expression in lymphoid organs.43, 44, 45 
Lymphotoxin-β also plays an important role in  development of Payer’s patches and colon-
associated lymphoid tissue.46 B cells expressing LTα1β2 control splenic macrophage 
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phenotype and important in maintaining subcapsular sinus macrophages recruiting CD169+ 
macrophages in marginal zone.7  
 LTαβ is expressed on activated T, B and Natural Killer (NK) cells as well as on 
subsets of resting B cells.47 Inducer cells characterised by CD4+CD3 ̶   expression, which are 
important in lymph node organogenesis express LT.48 During the developmental process 
lymphocytes that express LTαβ communicate with the cells that express the LTβR, triggering 
the secretion of chemokines such as CXCL13, CCL19 and CCL21 and upregulation of cell 
adhesion molecule.49, 50  
There are several reports showing that LTβR signalling is involved in autoimmunity. 
Treatment with anti-LTβ monoclonal antibody (mAb) showed effective preventiion of 
autoimmune encephalomyelitis (EAE) in rat models.44 Different roles played by LTα1β2+ B 
cells are summerised below (Fig. 1-5). 
Fig. 1-5: The role and function of LTαβ secreting B cells in lymphoid organ development. 
(Shen P., Fillatreau S., Nat Rev Immunol, 2015) 
There is evidence to indicate that LTβ can influence CD8 T cell priming to viral 
infection. In case of LCMV challenge, LTβ deficient mice (Ltβ–/–) showed poor CD8 T cell 
activity and failed to generate virus specific CD8 T cell response as well as memory CD8 T 
 
 
  16 
 
cell response.51  As a result of insufficient CD8 T cell priming Ltβ–/– mice failed to generate 
IFN-γ and showed delayed viral clearance.51  
In line with these results, we in our study found that viral replication of initial 
inoculum is essential for CD8 T-cell activation and priming. On the other hand, extracellular 
distribution of virus along the splenic conduits and virus replication in marginal zone is 
necessary for inducing type I interferon (IFN-I) response. The presence of LTβ is important 
for distribution of virus along the marginal zone; therefore, the lack of LTβ resulted in 
limited systemic production of IFN-I but in normal CD8 T-cell responses. 
 
1.4 Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) 
 Carcinoembryonic antigen (CEA) family is involved in intercellular binding 
interactions important for cellular growth and differentiation. These are subdivided into the-
CEA-related-cell adhesion molecules (CEACAM’s) and pregnancy specific glycoproteins 
(PSG’s) (Fig. 1-6).52 CEACAM’s usually mediate homophilic and/or heterophilic 
interactions with other CEACAM’s.53 
Fig. 1-6: Different types of CEACAM’s in human and their tissue expression  
(Grey-Owen SD., Blumberg R., Nat Rev Immunol., 2006, modified) 
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CEACAM1 is expressed by epithelial, endothelial, B and T lymphocytes and myeloid 
cells.54, 55 CEACAM1 consists of amino terminal, immunoglobulin-variable-region (IgV-
like) like domain followed by immunoglobulin constant-region-type-2-(IgC2-like) like 
domain.52 CEACAM1 also contains cytoplasmic and transmembrane domain. Isoforms with 
long cytoplasmic domain (CEACAM1-4L) contains two immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs), which usually transmit inhibitory signals.52 On the other hand, 
isoforms with short cytoplasmic tail (CEACAM1-4S) lacks ITIMs, but contains sequences 
that can bind to calmodulin56, tropomyosin and globular actin showing interaction with the 
cytoskeleton (Fig. 1-7).57  
Fig. 1-7: Different isotypes of CEACAM1 in human (Grey-Owen SD., Blumberg R., Nat 
Rev Immunol., 2006, modified) 
 
CEACAM1 has been shown to be involved in a variety of immune functions. 
CEACAM1 is expressed on almost all immune cells including B cells, T cells, NK cells, 
neutrophils, dendritic cells, granulocytes and monocytes. CEACAM1-L recruits SHP-1 and 
SHP-2 to its cytoplasmic tail in an ITIM dependent manner and has been shown to be 
important for inhibition of mouse epithelial tumour-cell growth. Whereas CEACAM1-4S has 
been shown to induce apoptosis in epithelial cells.58 CEACAM1 is also involved in B cell-
receptor mediated complex activation. Anti-CEACAM1 antibody (mAb) strongly triggered 
mouse B cells together with IgM crosslinking.59 Recently, it has been shown that CEACAM1 
expression is increased on B-cells and CEACAM1+ B cells were present in brain infiltrates of 
multiple sclerosis (MS) patients. Treatment with anti-CEACAM1 antibody resulted in 
blocking aggregation of B cell derived from MS patients.60 T cells also express CEACAM1 
in vivo during coeliac disease61 and in large intestine during inflammatory bowls disease.62 
Similarly, down regulation of CEACAM1expression in a non-tumorigenic cell line increased 
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its tumorigenic capacity63. Conversely, over expression of CEACAM1 in cancer cells supress 
their tumorigenic phenotype both in vitro and in vivo.63, 64 
In this study, we showed that intrinsic signalling of CEACAM1 is essential for 
generating efficient B-cell responses. Expression of CEACAM1 induced survival of 
proliferating B cells via the BTK/Syk/NF-κB-axis. Lack of this BCR signalling cascade in 
naive Ceacam1–/– mice limited the survival of B cells and hence total B cell numbers. Hence, 
when the Ceacam1–/– mice were challenged with cytopathic VSV, they could not induce 
neutralizing antibody responses and died early after infection. We found that CEACAM1 is a 
crucial regulator of B-cell survival, influencing B-cell numbers and is important for 
generating antiviral antibody responses. 
 
1.5  Viruses 
In this study, we used different strains of noncytopathic virus called lymphocytic 
choriomeningitis virus (LCMV) to check the role of enforced viral replication in innate and 
adaptive immune activation. We used LCMV strain WE (LCMV-WE), an acute virus strain 
and recombinant LCMV strain (rLCMV), to investigate the role of IFN-I in CD8 T-cell 
priming. To investigate the role of virus-specific antibodies on enforced virus replication and 
CD8 T-cell priming in addition to LCMV-WE we used LCMV strain Docile (LCMV-Docile) 
which induces chronic infection and persists longer in the host system. 
We also used cytopathic virus, vesicular stomatitis virus (VSV) to understand the role 
of CEACAM1 in antibody responses. 
 1.5.1 Lymphocytic choriomeningitis virus (LCMV) 
 The first strain used in our study is LCMV-WE. LCMV was discovered in 1934 by 
Charles Armstrong. It’s a noncytopathic arenavirus responsible for aseptic meningitis and 
encephalitis. The LCMV genome consist of two negative sense-single stranded RNA 
designated L and S.65, 66 LCMV infection is initiated by attachment of virus to the host 
receptors through the glycoproteins. It is then endocytosed and fusion of virus and vesicle 
membrane is formed followed by release of the ribonucleocapsid into the cytoplasm. 
 Different strains of LCMV generate different T cell responses and the clearance is 
also strain-dependent. So far four strains have been described. Neurotropic ‘’Clone 13’’ is a 
derivative of ‘’Armstrong’’ strain and hepatotropic ‘’docile’’ is a derivative of WE strain.67 
WE and Armstrong infection cause acute infection where the viral particles are cleared 
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within few days. On the other hand, docile and clone 13 cause chronic infection and it can 
take up to few weeks to clear the viral particles. Mice infected with lower dose such as 100 
Plaque forming units (PFU) of LCMV-Docile cleared virus within 2-4 weeks because of 
normal cytotoxic T cell response (CTL), whereas mice infected with higher doses (1 × 107 
PFU) generate weak CTL responses and the viral particles are detectable until day 280 post 
infection.68 On the other hand with an intermediate dose of 1 × 104 PFU of LCMV-Docile 
mice failed to cleared the virus and exhibited high immunopathology.68 The balance between 
the viral load and T cell response is shown below (Fig. 1-8). 
 
 
 
 
 
 
 
 
Fig. 1-8: Balance between the viral load and T cell response in terms of disease outcome. 
(Cornberg M. et al., Front. Immun., 2013, modified) 
 Disease progression in LCMV-Docile or LCMV-Clone13 infection is due to 
dysfunction of T cells. Exhaustion is a state of T-cell where the ability to produce cytokines 
such as IL-2 and higher proliferative and ex vivo capacities are lost. The production of 
antiviral cytokines such as TNF-α and IFN-γ are abolished and in final stage the CD8 T cells 
are deleted.69 As a result of high activation due to viral load the hepatocytes in liver are 
targeted by CD8 T cells which results in high levels of immunopathology in the infected 
organism. 
 1.5.2 Vesicular Stomatitis Indiana Virus (VSV)  
 Another virus we used in our study is Vesicular Stomatitis Virus (VSV) belonging to 
the family Rhabdoviridae. VSV is a cytopathic virus and the control of the virus is highly 
dependent on antiviral antibodies generated by B cells. The genome of VSV is single 
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negative sense-RNA that encodes five major proteins: G protein (G), large protein (L), 
phosphoprotein, matrix protein (M) and nucleoprotein. 
VSV exhibits exclusive neurotropism, and if not controlled early enough by immune 
responses can cause paralytic disease after 5 to 6 days of infection invading the central 
nervous system by breaching the blood-brain barrier reulting in death.70  
 In this study, we used VSV to check the role of CEACAM1 in antiviral antibody 
generation. We injected VSV to Wild type (WT) and Ceacam1–/– mice and found that lack of 
CEACAM1 hinders the production of anti-VSV neutralizing antibodies. Total neutralizing 
antibody titers in Ceacam1–/– mice were significantly lower than WT mice. Interestingly, 
neutralizing IgG antibody generation was completely missing in the Ceacam1–/– mice. To 
check if the viral replication in the spleen was the main reason to generate anti-VSV 
antibodies we used ultraviolet inactivated (UV) VSV and measured the antibody response 
and we did not see any secretion of total (IgM + IgG) as well as IgG neutralizing antibodies. 
 In the first part of the thesis, using LCMV-WE and rLCMV we showed how viral 
replication of the initial inoculum is essential for activating virus-specific CD8 T cells. In 
contrast, extracellular distribution of virus along the splenic conduits is necessary for 
induction of systemic levels of type I interferon (IFN-I). In second part, we investigated the 
role of CEACAM1 on B-cell survival and antiviral antibody secretion using the VSV model. 
In the last part of the thesis we show that upon recall infection virus specific antibodies allow 
viral replication in the splenic marginal zone. This replication was necessary for priming 
CD8 T cells and control of chronic virus infection. In contrast, memory CD8 T cells inhibited 
virus replication in marginal zone but failed to protect the mice upon chronic virus infection. 
 
1.6 Mouse models used  
❖ P14 × CD45.1 
These mice express a T-cell receptor (TCR) specific for the LCMV glycoprotein 33 
to 41 (GP-33-41) as a transgene. Splenocytes from these mice were used in adaptive 
transfer experiments. Because T-cells from these mice express TCR specific against 
LCMV-GP-33-41, the T cell response is initiated immediately and can be measured 
by staining against the congenic marker CD45.1.71 
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❖ Usp18–/–  
In these mice, the Ubiquitin-specific peptidase 18 (USP18), is knocked out. USP18 is 
also known as ISG15 and it is a negative regulator of Type I and Type III Interferon 
signalling.72 
 
❖ Jh–/– 
These mice carry a deletion of the endogenous murine J segments of the Ig heavy 
chain locus. Lack of all four JH gene segment results in cells that cannot produce a 
complete, recombined version of the variable region of the heavy chain. These mice 
lack mature B cells in bone marrow and peripheral organs as well. However, these 
mice have normal T cell response.73 
 
❖ Ltbr–/– 
Lymphotoxin beta receptor (Ltbr–/–) mice lack Payer’s patches, colon associated 
lymphoid tissues and lymph nodes. These mice do not develop normal splenic 
architecture and marginal zone in spleen is absent as well.46 
 
❖ Ltbfl/fl × CD19cre 
These mice lack lymphotoxin solely on B cells. Only the splenic architecture of the 
mice is affected but these mice develop normal Payer’s patches and have functional 
lymph nodes.74 
 
❖ CD169-DTR 
These transgenic mice have human diphtheria toxin receptor (DTR) under the 
promoter of CD169 gene. Hence the CD169+ marginal zone macrophages can be 
selectively depleted by administration of diphtheria toxin.75  
 
❖ Ceacam1–/– 
These mice lack CEACAM1 on all cells and is used to study the effect of CEACAM1 
on B cell development and antiviral antibody production.76 
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❖ Tcrab–/– 
These transgenic mice lack alpha beta T-cell receptor. There are normal number of 
CD4 ̶ CD8 ̶  T cells but lack mature CD4 and CD8 T cells.77 
 
❖  Aid–/– 
The activation induced cytidine deaminase is expressed in germinal centre B cells. 
These mice lack immunoglobulin class switch recombination, immunoglobulin 
somatic hypermutations and lymph node hyperplasia.78 
  
❖ sIgM–/– 
These mice lack the secreted form of IgM in serum.79 
 
❖ Myd88/Trif –/– 
There mice are defective in both TLR-3 and TLR-4 mediated expression of IFN-β 
and activation of IRF-3.80 
 
❖ Baffr –/– 
These transgenic mice lack receptor for B-cell activating factor (BAFF). These mice 
exhibit defective splenic architecture, shows abnormal B cell development and 
impaired T-cell dependent antibody formation.81 
 
❖ Fcgr2b –/– 
These transgenic mice shows elevated levels of immunoglobulin in response to 
thymus dependent and independent antigens.82 
 
❖ Vi10 × CD45.1 
These transgenic mice express VSV-specific BCR as a transgene. Splenocytes from 
these mice were used for transfer experiments. The antibody response can be 
measured by neutralization assay from serum.83 
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❖ Prf1 –/– 
Mice transgenic for Perforin do not lyse virus-infected or allogeneic fibroblasts or 
natural killer target cells in vitro. These mice also failed to clear LCMV. This 
molecule is important for T-cell and NK-cell mediated killing.84 
 
❖ B2m –/– 
These mice are devoid of β2-Microglobulin which is important for MHC-I expression 
and CD8+ T-cell development. Hence in antigen challenge these mice lack cytotoxic 
T-cell function.85 
 
❖ KL25 × CD45.1 
These transgenic mice have LCMV specific B-cell response. These mice were used 
for adoptive transfer experiments.86 
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2.1   Abstract 
The induction of innate and adaptive immunity is essential for controlling viral infections. 
Limited or overwhelming innate immunity can negatively impair the adaptive immune 
response. Therefore, balancing innate immunity separately from activating the adaptive 
immune response would result in a better antiviral immune response. Recently, we 
demonstrated that Usp18-dependent replication of virus in secondary lymphatic organs 
contributes to activation of the innate and adaptive immune responses. Whether specific 
mechanisms can balance innate and adaptive immunity separately remains unknown. In this 
study, using lymphocytic choriomeningitis virus (LCMV) and replication-deficient single-
cycle LCMV vectors, we found that viral replication of the initial inoculum is essential for 
activating virus-specific CD8+ T cells. In contrast, extracellular distribution of virus along the 
splenic conduits is necessary for inducing systemic levels of type I interferon (IFN-I). 
Although enforced virus replication is driven primarily by Usp18, B cell-derived 
lymphotoxin beta contributes to the extracellular distribution of virus along the splenic 
conduits. Therefore, lymphotoxin beta regulates IFN-I induction independently of CD8+ T-
cell activity. We found that two separate mechanisms act together in the spleen to guarantee 
amplification of virus during infection, thereby balancing the activation of the innate and 
adaptive immune system. 
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2.2  Introduction 
During infection with a persistence-prone virus, type I interferon (IFN-I) and CD8+ T 
cells mediate the control of virus in infected cells. CD8+ T cells are activated early by viral 
replication; however, prolonged viral replication results in CD8+ T-cell exhaustion and 
persistence of virus. Recently, striking data showed that IFN-I is like a yin yang for 
controlling virus [1,2]. On the one hand, IFN-I is clearly antiviral, and it can influence the 
very early viral replication that can affect the course of persistent infection [3]. On the other 
hand, it induces programmed death ligand 1 (PD-L1) and interleukin IL-10 and thereby 
drives CD8+ T-cell exhaustion [1,2]. Therefore, limited production of IFN-I in the presence 
of highly activated CD8+ T cells results in severe immunopathology [4]. 
Lymphotoxins play an important role in several immunological processes, including 
lymph node development during embryogenesis, generation and activation of dendritic cells 
(DCs), and homeostatic control of chemokine expression in lymphoid organs [5,6,7]. 
Lymphotoxin beta (Ltb) plays a role in splenic architecture, developing conduits along the 
marginal zone and recruiting CD169+ macrophages [8,9]. 
Recently we found that, during acute viral infection, viral replication in the marginal 
zone of the spleen and lymph nodes is essential for activating the innate and adaptive 
immune responses. This replication is dependent on ubiquitin-specific peptidase 18 (Usp18); 
therefore, the lack of Usp18 blunts the innate and adaptive immune responses [10,11]. 
Although Ltb obviously enhances replication in secondary lymphatic organs [9], the interplay 
between Ltb and Usp18 remains unknown.  
In the present study, using lymphocytic choriomeningitis virus (LCMV), we found 
that extracellular distribution of virus along the splenic conduits is necessary for inducing 
systemic levels of IFN-I but not for inducing virus-specific CD8+ T cells. Only the presence 
of Ltb-induced conduits allows the distribution of virus along the marginal zone; therefore, 
the lack of Ltb results in limited systemic production of IFN-I but in normal CD8+ T-cell 
responses. 
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2.3   Methods 
2.3.1 Mice 
P14/CD45.1 mice expressing a T-cell receptor (TCR) specific for LCMV 
glycoproteins 33 to 41 (LCMV-GP33-41) as a transgene were maintained on a C57BL/6 
background and were used for adoptive transfer experiments [13]. Usp18–/– mice were 
generated in the Dong-ER Zhang laboratory (University of California san Diego, La jolla 
CA, USA) and were bred heterozygously on a Sv129 × C57BL/6 background, generation F4; 
these mice were directly compared with littermate control animals. Heavy chain joining gene 
null (Jh–/–) mice were maintained on a C57BL/6J background; lymphotoxin beta receptor 
null (Ltbr–/–) mice were maintained on a C57BL/6N background. Conditionally targeted Ltb 
(Ltbfl/fl) mice were crossed with CD19-Cre transgenic mice, and CD19-Cre-negative mice 
were used as littermate controls [14]. CD169-diphtheria toxin receptor (DTR) mice were 
maintained on a C57BL/6J background. 
 
 2.3.2 Virus and plaque assays 
 LCMV strain WE was originally obtained from F. Lehmann- Grube (Heinrich Pette 
Institute, Hamburg, Germany) and was propagated in L929 cells. Mice were infected 
intravenously with LCMV-WE at the indicated doses. Viral titers were measured with a 
plaque-forming assay using MC57 cells, as previously described [15]. We used recombinant 
LCMV (rLCMV; kindly provided by Daniel Pinschewer, University of Basel, Switzerland) 
to produce rLCMV vectors expressing a mutated version of LCMV-GP, which fails to confer 
viral infectivity but remains antigenic. We titrated these vectors according to standard 
procedures [16]. 
 
 2.3.3 Lymphocyte transfer 
 Splenocytes from P14/CD45.1 mice were injected intravenously into Usp18–/– mice 
and littermate control mice. One day later, mice were infected with rLCMV (6 × 104 plaque-
forming units [PFU]), and the percentage of P14/CD45.1 T cells in the spleen was assessed 
by flow cytometry. 
 
 2.3.4 Diphtheria toxin 
 Diphtheria toxin was purchased from Sigma (ST Louis, Missouri, USA) and was 
injected intraperitoneally on day  ̶ 3 and day 2 at a dose of 30 µg/kg. 
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 2.3.5 Cell culture and generation of bone marrow  ̶  derived macrophages 
Primary macrophages were generated by isolating bone marrow cells from femurs 
and tibias of mice. Macrophages were generated by culturing bone marrow cells in very low 
endotoxin Dulbecco's Modified Eagle's Medium (VLE-DMEM) supplemented with 10% 
(v/v) fetal calf serum (FCS), 0.1% (v/v) b-mercaptoethanol (b-ME), and 10 ng/ml 
macrophage colony-stimulating factor (M-CSF). After 9 days, macrophages were harvested 
for use in subsequent experiments. Recombinant mouse lymphotoxin α2/β1 was purchased 
from R&D Systems (Minneapolis, USA). 
 
 2.3.6 Flow cytometry 
Tetramers were provided by the National Institutes of Health (NIH) Tetramer Core Facility 
(Emory University, Atlanta, GA, USA). Cells were stained with allophycocyanin (APC)-
labelled GP33 major histocompatibility complex (MHC) class I tetramer (GP33/H-2Db) for 
15 min at 37 °C. After incubation, the samples were stained with anti-CD8 (eBiosciences, 
San Diego, USA) for 30 min at 4 °C. Absolute numbers of GP33-specific CD8+ T cells were 
calculated by fluorescence-activated cell sorting (FACS) analysis using fluorescent beads 
(BD Biosciences, San Jose, CA, USA). For measurement of intracellular IFN-γ, cells were 
stimulated with glycoprotein 33 (GP33) or nucleoprotein 396 (NP396), fixed with 2% 
formaldehyde for 10 min followed by permeabilization with saponin, and stained with anti-
IFN-γ or tumor necrosis factor (TNF-α) antibodies (eBioscience). For MHC-I expression, 
Blood was stained on day 4 with anti CD8, anti CD4 and anti MHC-I (eBioscience) 
antibodies. 
 
 2.3.7 ELISA 
Enzyme-linked immunosorbent assays (ELISA) for IFN-α were performed according to the 
manufacturer's protocol (PBL Interferon Source, New Jersey, USA). 
 
 2.3.8 Histology 
Conventional staining was performed as previously described [11]. Briefly, snap-frozen 
tissue was stained with rat anti-mouse polyclonal antibody to LCMV NP (VL4; made in 
house). Polyclonal anti-rat biotin antibody (eBioscience) and anti-biotin streptavidin 
peroxidase antibody (Thermo Scientific, Fremont, CA, USA) were then added before 
visualization with a 2-solution diaminobenzidine (DAB) staining kit (Invitrogen, Carlsbad, 
CA, USA), after which the tissue was stained with hematoxylin. Immunofluorescence 
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analyses of snap-frozen tissue were performed with anti-F4/80 (eBioscience), and anti-
CD169 (Acris) antibodies. Mouse nonspecific goat anti-guinea pig immunoglobulin (IgG; 
Jackson ImmunoResearch, West Grove, PA, USA) antibody was injected into mice to check 
in vivo the early distribution of the antibody. 
 
2.4   Results 
2.4.1  Viral amplification is suppressed in peripheral organs but is allowed in    
                     spleen and lymph nodes 
During systemic infection, macrophages in the liver (Kupffer cells) capture most of 
the virus. This activity is observed when real time polymerase chain reaction (RT-PCR) for 
LCMV is performed 30 min after infection (Fig. 1A). If Kupffer cells are depleted with 
Clodronate-Liposome, the uptake of virus by the liver is reduced, whereas viral uptake by 
spleen, kidney and lung is increased (Fig.1A). In normal case, without clodronate treatment, 
virus that is captured in the liver cannot amplify to detectable levels (Fig. 1B); however, 
virus can replicate only in spleen and lymph nodes (Fig. 1B). Histologic analysis of the 
spleen demonstrates that virus spreads along the conduits of the marginal zone; thus, once a 
lymph follicle is infected, the virus is quickly distributed along the marginal zone in the 
spleen (Fig. 1C). These findings indicate that the spread of virus along marginal zone 
conduits is essential for viral replication in the spleen. 
 
 2.4.2  Lack of lymphotoxin beta limits the flow along the marginal zone 
Next, we questioned whether spread of the virus is regulated independently of viral 
replication and how these diverse mechanisms are regulated. We speculated that LTb is an 
important contributor to viral spread along the marginal zone; therefore, we infected wild-
type (WT) and Ltbfl/flCD19-Cre (which lack LTb specifically on B cells) mice with LCMV 
and performed histologic analysis of the spleens. Ltbfl/flCD19-Cre mice exhibited several 
spots of infected cells but no distribution along the marginal zone (Fig. 2A). This finding 
suggests that Ltb is indeed necessary for viral distribution within the marginal zone of the 
spleen. We speculated that the lack of conduits in mice lacking the Ltb receptor (Ltbr–/–) 
limits flow along the marginal zone, a factor that could explain the limited spread of virus. 
To explore this speculation, we injected fluorescent beads into WT and Ltbr–/– mice. 
Histologic staining detected only limited numbers of beads in the marginal zone area of Ltbr–
 
 
  36 
 
/– mice compared to WT mice (Fig. 2B), a finding supporting the hypothesis that flow of the 
virus along the marginal zone of the spleen is limited in the absence of Ltb. To validate our 
finding we then injected mice with xenogenous nonspecific antibody labeled with fluorescent 
cyanine dye into WT and Ltbr–/– mice and analyzed its distribution after 2 min. In WT mice, 
antibody stained the conduits along the marginal zone of the spleen (Fig. 2C). In contrast, 
Ltbr–/– mice exhibited limited staining along the marginal zone area (Fig. 2C). Liver vessels 
were not affected by Ltb, a finding suggesting that the formation of conduits is specifically 
sensitive to Ltb (Fig. 2C) and are important for the cell to cell distribution of the viral 
particles. In conclusion, we found that the absence of Ltb limits flow of the antigen along the 
marginal zone, and this limitation in turn reduces the distribution of virus in the spleen. 
 
2.4.3 Usp18 and lymphotoxin beta allow viral replication in the spleen 
Next, we questioned how the limited viral spread in the marginal zone influences the 
production of virus in the spleen. First, we infected bone marrow derived macrophages of 
WT and Usp18 deficient mice with LCMV and measured the virus titer in the supernatant 
after 24 h. We found that Usp18 enhances LCMV replication on a cellular level, as 
demonstrated by in vitro study (Fig. 3A). Similarly, in vivo study showed that Usp18 
enhances viral replication as WT mice have higher titer of LCMV relative to Usp18–/– mice 
(Fig. 3B). In contrast, the lack of Ltb does not reduce viral replication in vitro (Fig. 3C). 
Moreover, treating cells with recombinant LTα2/β1 did not reduce viral titer in the 
supernatant (Fig. 3C). Interestingly, in vivo, Ltbr–/– mice exhibit limited viral replication 
(Fig. 3D). To see whether this limited viral replication was due to reduction of CD169+ 
macrophages, we depleted CD169+ cells in CD169-DTR mice and infected them with 
LCMV. The depletion of CD169+ macrophages enhances viral replication (Fig. 3E and 
Supplementary Figure 1) which means that the limited replication in Ltbr–/– mice is not 
caused by the reduction in the number of CD169+ macrophages. Instead, viral replication is 
limited by Ltb-derived B cells, because viral replication is similarly reduced in Jh–/– and 
Ltbfl/flCD19-Cre mice (Fig. 3F). Therefore, we conclude that both Usp18 and Ltb are 
essential for enforced viral replication in the spleen. 
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2.4.4  Usp18 and lymphotoxin beta are essential for inducing systemic type I  
                     interferon production, but only Usp18 influences CD8+ T-cell priming 
We found that Usp18 influences viral replication, whereas Ltb guarantees viral spread 
along the marginal zone. Both mechanisms are necessary for viral replication in the spleen. 
To determine how Usp18 and Ltb influence the innate and adaptive immune responses, we 
infected Usp18–/– mice with 200 PFU of LCMV and measured IFN-I in the serum. We found 
that early viral replication is essential for IFN-I production (Fig. 4A). Similarly, IFN-I 
production is strongly impaired in Ltbfl/flCD19-Cre mice (Fig. 4B). Although viral replication 
was not completely inhibited in both Usp18–/– and Ltbfl/flCD19-Cre mice, this replication was 
not enough to trigger IFN-I production. Next, we wanted to examine the effect of Usp18 and 
Ltb on adaptive immune responses. As expected, the lack of Usp18 limits the magnitude of 
CD8+ T-cell responses (Fig. 4C). Lately, it was shown that IFN-I can protect CD8+ T cells 
from killing by NK cells through upregulation of MHC-I [17]. We wondered whether the 
reduction of CD8+ T cell numbers was due to lack of IFN-I production. To check this, we 
measured MHC-I expression on T cells on day 4 after infection. We found that Usp18-
deficient T cells showed higher MHC-I expression than WT T cells (Supplementary Figure 
2) which can be explained due to a stronger IFN-I signalling in these cells. 
In contrast to Usp18–/– mice, Ltbfl/flCD19-Cre mice exhibit CD8+ T-cell responses 
similar to those of WT mice (Fig. 4D). This finding suggests that viral spread along the 
marginal zone is essential for IFN-I production but not for CD8+ T-cell priming. 
 
2.4.5  Extracellular spread of virus is essential for inducing systemic type I  
                     interferon production but not for inducing CD8+ T-cell responses 
To determine whether the spread of virus along the marginal zone is essential for 
activating the innate but not the adaptive immune response, we used a single-cycle virus 
(rLCMV). Because this virus does not express the full LCMV-GP, cells infected with 
rLCMV do not produce infectious virus particles. However, viral genome transcription and 
replication are allowed within the cells that were initially infected. We infected C57BL/6 
mice with LCMV or rLCMV. We found that, LCMV induces large amounts of serum IFN-I 
at almost all infectious doses tested, whereas rLCMV does not induce detectable levels of 
systemic IFN-I (Fig. 5A). Therefore, we conclude that the spread of virus is essential for 
inducing IFN-I.  
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We next examined the role of rLCMV in activating CD8+ T cells. We found that, 
compared to LCMV infection, infection with the rLCMV vector induces weaker but still 
potent virus-specific CD8+ T-cell responses (Fig. 5B). As few as 100 infectious units 
produce measurable CD8+ T-cell responses. Immunization with 105 PFU of vector results in 
frequencies of epitope-specific CD8+ T cells that are similar to those produced by WT virus 
(Fig. 5B). To check whether single-cycle rLCMV exhibits limited CD8+ T-cell expansion in 
the absence of Usp18, we transferred splenocytes from P14/ CD45.1 mice into WT and 
Usp18–/– mice, These mice express a T-cell receptor (TCR) specific for LCMV glycoproteins 
33 to 41 (LCMV-GP33-41). We infected both groups with rLCMV and measured the number 
of transferred CD8+ T cells. We found that CD8+ T cells expand much less in the absence of 
Usp18 compared to WT mice (Fig. 5C). These findings led us to conclude that the induction 
of systemic IFN-I depends on extracellular transfer and dissemination of virus. In contrast, 
replication of the initial virus inoculum is sufficient for inducing the production of virus-
specific CD8+ T cells. 
 
2.5   Discussion 
The results of this study show that both Usp18 and Ltb contribute to viral replication 
in the spleen. Whereas Usp18 directly influences virus replication, Ltb guarantees the spread 
of LCMV along the marginal zone. Although LCMV replication is sufficient for CD8+ T-cell 
activation, both effects, i.e., virus replication and extracellular virus transfer, are necessary 
for inducing systemic IFN-I. 
These two mechanisms of virus propagation may influence the outcome of viral 
infection. This possibility is of special interest because both mechanisms influence 
replication separately. Usp18 is strongly induced by IFN-I, whereas Ltb is produced 
constantly in the spleen and is mainly influenced by the number of B cells in a lymph follicle. 
Therefore, various infections could regulate both mechanisms separately. In the presence of 
B cells and high levels of Ltb, IFN-I is induced more efficiently. 
We found that the spread of virus along the marginal zone is essential for the 
induction of systemic IFN-I. During LCMV infection, plasmacytoid dendritic cells (pDCs) 
produce large amounts of IFN-I [18,19], for which the IFN-I-activating receptor retinoic 
acid-inducible gene-I (RIG-I) is at least partially responsible [20]. We determined that B cell-
derived Ltb is an important contributor to extracellular distribution of virus along the 
 
 
  39 
 
marginal zone. However, it remained unclear why this distribution of virus is essential for 
IFN-I induction. One explanation could be that only large amounts of viral RNA can 
sufficiently activate pDCs. A second explanation could be that the composition of the cell 
membrane of infected cells along the marginal zone is different from that of other cell types; 
therefore, virus particles received from these cells could be more likely to infect pDCs. 
Indeed, recent findings show that the composition of the cell membrane can influence viral 
tropism [21]. A third explanation could be that this distribution of virus is important for 
infecting cells that are near pDCs. Consequently, those pDCs may sense the presence of 
infected cells and produce IFN-I. Recent findings have shown that uninfected pDCs can 
produce IFN-I by sensing infected cells; this mechanism is independent of intrinsic viral 
replication in pDCs [22]. However, more studies are needed for determining which of these 
explanations may be correct. 
It remains unclear why CD8+ T cells but not IFN-α-producing cells can be activated 
by a single-cycle virus. We consider that the amount of viral protein and viral RNA within an 
infectious particle is limited compared to that in a virus-infected cell. Therefore, if one 
infectious rLCMV particle infects a DC, this virus-infected DC can probably generate a 
sufficient virus-specific CD8+ T-cell response. 
Recent publications reported that an overwhelming IFN-I response can induce IL-10 
and PD-L1, which then affect the exhaustion of CD8+ T cells [1,2]. Another supporting study 
showed a negative role of IFN-b in controlling persistent viral infection [3]. In light of our 
findings, we suggest that inhibiting the extracellular spread of virus may limit the virus-
induced production of IFN-I and thereby may prevent the exhaustion of CD8+ T cells. 
Various antiviral drugs target separate virus pathways. We suggest that antiviral drugs, which 
allow viral replication but block the release of virus particles, may inhibit viral propagation 
but still allow the priming and activation of antiviral CD8+ T cells. If so, treatment with these 
drugs may provide the most effective long-term protection against virus. 
 Further studies are needed to be done to show whether these two mechanisms may 
influence additionally the peripheral IFN-II production and thereby contribute to relapse of 
lupus erythematosus [23,24]. 
 In conclusion, we found that viral replication and extracellular viral spread are two 
separate mechanisms of enforced viral replication. Whereas viral replication is essential for 
activation of the innate and adaptive immune system, extracellular viral spread primarily 
affects systemic IFN-I production. 
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2.8  Figure Legends 
2.8.1 Figure 1: Viral amplification is suppressed in peripheral organs but allowed  
                     in spleen and lymph nodes.  
(A) C57BL/6 mice were injected with empty liposomes (as controls) or were depleted of 
macrophages with clodronate liposomes. After one day, mice were infected with lymphocytic 
choriomeningitis virus (LCMV; 2 × 106 plaque-forming units [PFU]), and after 30 min 
copies of LCMV were quantified by real time polymerase chain reaction (RT-PCR) (n = 6). 
(B) C57BL/6 mice were infected with LCMV (200 PFU), and viral titers were determined in 
various organs at indicated time points (n = 4). (C) Histologic staining for LCMV 
nucleoprotein (NP) was performed on splenic sections from C57BL/6 mice infected 
intravenously with LCMV (200 PFU) for three days (n = 3; scale bar in main images, 500 
µm; inlets, 100 µm). 
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 2.8.2 Figure 2: Lack of lymphotoxin beta limits flow along the marginal zone. 
(A) Results of conventional histologic analysis of splenic sections from wild-type (WT) mice 
and conditionally targeted lymphotoxin beta (Ltbfl/fl) CD19-Cre mice infected with 
lymphocytic choriomeningitis virus strain WE (LCMV-WE; 200 plaque-forming units 
[PFU]) for 3 days. LCMV, brown (n = 3; scale bar main images, 500 µm; inlets, 100 µm). 
(B) Immunofluorescent staining of spleen sections from C57BL/6 mice 10 min after being 
injected with fluorescent beads. Beads, green; CD169, red; F4/80, blue (n = 3; scale bar, 100 
µm). (C) Immunofluorescent staining of spleen and liver sections from WT and lymphotoxin 
beta receptor deficient (Ltbr–/–) mice 2 min after injection with anti-guinea pig 
immunoglobulin (IgG), red (n = 5; scale bar, 100 µm). (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this article.) 
 
 2.8.3 Figure 3: Ubiquitin-specific peptidase 18 and lymphotoxin beta allow viral  
                     replication in the spleen. 
(A) Bone marrow-derived macrophages from ubiquitin-specific peptidase 18 deficient 
(Usp18–/–) mice and littermate control mice were infected with lymphocytic choriomeningitis 
virus strain WE (LCMV-WE; multiplicity of infection [MOI], 1). After 24 h, viral titer in the 
supernatant was determined (n = 4). (B) Usp18–/– and littermate control mice were infected 
intravenously with LCMV-WE (200 plaque-forming units [PFU]). After 3 days, viral titers in 
the spleen were determined (n = 3). (C) Bone marrow-derived macrophages from wild-type 
(WT) and lymphotoxin beta receptor deficient (Ltbr–/–) mice were infected with LCMV-WE 
(MOI, 1) and treated with interferon alpha (IFN-α; 50 U/ml), (lymphotoxin α2/β1; 100 
ng/ml), or both, or were left untreated. After 24 h, viral titer in the supernatant was 
determined (n = 3 - 6). (D) WT and Ltbr–/– mice were infected intravenously with LCMV-
WE (200 PFU). After 3 days, viral titers in the spleen were determined (n = 3 - 4). (E) 
C57/BL6 or CD169 diphtheria toxin receptor (CD169-DTR) mice were treated with 
diphtheria toxin and infected with LCMV (200 PFU). After 2 days, viral titers in the spleen 
were determined (n = 5). (F) Heavy chain joining gene deficient (Jh–/–), conditionally 
targeted Ltb (Ltbfl/fl) CD19-Cre, and control mice were infected intravenously with LCMV-
WE (200 PFU). After 3 days, viral titers in the spleen were determined (n = 3 - 4). 
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 2.8.4 Figure 4: Ubiquitin-specific peptidase 18 and lymphotoxin beta are essential  
                     for inducing systemic type I interferon, but only ubiquitin-specific peptidase  
                    18 influences the priming of CD8+ T cells. 
(A) Ubiquitin-specific peptidase 18 deficient (Usp18–/–) mice and littermate control mice 
were infected intravenously with 200 PFU of lymphocytic choriomeningitis virus (LCMV). 
Interferon alpha (IFN-α) levels in serum were determined by enzyme-linked immunosorbent 
assay (ELISA) at the indicated time points (n = 4). (B) Wild-type (WT) and conditionally 
targeted lymphotoxin beta (Ltbfl/fl)CD19-Cre mice were infected intravenously with 200 
plaque-forming units (PFU) of LCMV strain WE. IFN-α levels were measured in the serum 
by ELISA at the indicated time points (n = 3-7). (C) Fluorescence-activated cell sorting 
(FACS) analysis of CD8+ T cells positive for glycoprotein (GP33), nucleoprotein 396 
(NP396), and IFN-γ in splenocytes from Usp18–/– and littermate control mice on day 30 after 
infection with 200 PFU LCMV-WE and six hours after re-stimulation with GP33 peptide or 
NP396 peptide (n = 4). (D) FACS analysis of GP33+ IFN-γ+ CD8+ T cells and GP33+ tumor 
necrosis factor TNF-α+ CD8+ T cells in splenocytes from (Ltbfl/fl)CD19- Cre mice and control 
mice on day 14 after infection with 200 PFU LCMV-WE and six hours after re-stimulation 
with GP33 peptide (n = 5-8). n.s., not statistically significant. 
 
 2.8.5 Figure 5: Extracellular spread of virus is essential for inducing systemic  
                     type I interferon but not for inducing a CD8+ T-cell response. 
(A) C57BL/6 mice were infected intravenously with the indicated doses of lymphocytic 
choriomeningitis virus strain WE (LCMV-WE) or recombinant LCMV (rLCMV). Interferon 
alpha (IFN-α) in the serum was measured by enzyme-linked immunosorbent assay (ELISA) 
at the indicated time points (n = 3). (B) Percentages of nucleoprotein 396 (NP396)-specific 
and glycoprotein 33 (GP33)-specific CD8+ T cells in blood were determined on day 9 after 
infection with the indicated doses of LCMV or rLCMV (n = 3-5, (virus dose 20,000 PFU; 
Tet-GP33+ n = 2; one of two experiment is shown)). (C) We adoptively transferred 107 
splenocytes from P14/CD45.1 mice into Ubiquitin-specific peptidase 18 deficient (Usp18–/–) 
or wild-type (WT) littermate control mice. After 24 h, mice were infected intravenously with 
rLCMV (6 × 104 plaque-forming units [PFU]). Absolute number of CD45.1+ CD8+ T cells in 
total lymphocytes in blood and spleen was determined (n = 3-6). 
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 2.8.6 Supplementary Fig. 1: Lymphocytic choriomeningitis virus replicates in the  
                     absence of CD169+ macrophages.  
Wild-type (WT) C57BL/6 and CD169 diphtheria toxin receptor (CD169-DTR) mice were 
treated with diphtheria toxin (30 μg/kg) three days before being infected with lymphocytic 
choriomeningitis virus strain WE (LCMV-WE; 2 × 106 PFU). After 24 hours, 
immunohistologic staining for LCMV nucleoprotein was performed on splenic sections 
(n = 3; scale bar main images, 500 μm; inlets, 100 μm). 
 2.8.7 Supplementary Fig. 2: Usp18 deficient T cells have higher MHC-I   
                     expression after LCMV infection. 
Ubiquitin-specific peptidase 18 deficient (Usp18−/−) mice (continuous line) and littermate 
control mice (dotted line) were infected intravenously with 200 PFU of lymphocytic 
choriomeningitis virus (LCMV). On day4, MHC-I expression was measured on T cells in the 
blood. 
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Figure 2-1: Viral amplification is suppressed in peripheral organs but allowed in spleen 
and lymph nodes. 
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Figure 2-2: Lack of lymphotoxin beta limits flow along the marginal zone. 
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Figure 2-3: Ubiquitin-specific peptidase 18 and lymphotoxin beta allow viral replication in 
the spleen. 
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Figure 2-4: Ubiquitin-specific peptidase 18 and lymphotoxin beta are essential for 
inducing systemic type I interferon, but only ubiquitin-specific peptidase 18 influences the 
priming of CD8+ T cells. 
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Figure 2-5: Extracellular spread of virus is essential for inducing systemic type I 
interferon but not for inducing a CD8+ T-cell response. 
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Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2-1: The depletion of CD169+ macrophages enhances viral 
replication 
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Supplementary Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2-2: Usp18-deficient T cells showed higher MHC-I expression 
than WT T cells 
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3.1  Abstract 
B cells are essential for antiviral immune defence because they produce neutralizing 
antibodies, present antigen and maintain the lymphoid architecture. Here we show that 
intrinsic signalling of CEACAM1 is essential for generating efficient B-cell responses. 
Although CEACAM1 exerts limited influence on the proliferation of B cells, expression of 
CEACAM1 induces survival of proliferating B cells via the BTK/Syk/NF-κB-axis. The 
absence of this signalling cascade in naive Ceacam1–/– mice limits the survival of B cells. 
During systemic infection with cytopathic vesicular stomatitis virus, Ceacam1–/– mice can 
barely induce neutralizing antibody responses and die early after infection. We find, 
therefore, that CEACAM1 is a crucial regulator of B-cell survival, influencing B-cell 
numbers and protective antiviral antibody responses. 
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3.2  Introduction 
B cells are central players in initiating a rapid antiviral immune response. Their main 
functions are producing virus-specific antibodies, presenting antigen and participating in 
building the splenic architecture1–4. Three subsets of B cells are important contributors to 
immune responses against pathogens: B1, marginal zone (MZ) and follicular B cells5,6. B1 B 
cells usually seed the peritoneal and pleural cavities and develop T-cell-independent antibody 
responses against bacterial antigens7. B1 B cells are also responsible for generating the so 
called natural antibodies that are detectable in naïve mice that have not experienced antigen7. 
MZ B cells are located in the splenic MZ, where they have direct contact with blood-borne 
pathogens. Therefore, antigen-activated MZ B cells usually respond hours after infection and 
build the specific antibody response early after infection5. Antigen-activated follicular B cells 
move to germinal centres, where the antibody’s affinity matures, and switch classes by 
recombining to mount long-lasting high affinity immunoglobulin G (IgG) antibody responses 
against pathogens5. 
Once B cells leave the bone marrow, two important signals determine their fate. First, 
tonic signalling by the B-cell receptor (BCR) in the absence of antigen is essential for the 
further differentiation and survival of mature B cells8. Second, signalling via the B-cell-
activating factor (BAFF) receptor strongly contributes to B-cell survival9. BCR activation of 
B cells leads to phosphorylation of Bruton’s tyrosine kinase (BTK), a member of the Tec 
family of non-transmembrane protein tyrosine kinases (PTKs)10,11. BTK phosphorylation 
after BCR ligation leads to the activation of canonical nuclear factor-κ light-chain enhancer 
of activated B (NF-κB) cell pathway, in addition to nuclear factor of activated T (NFAT) 
cells and extracellular signal-regulated kinase (ERK) pathways12,13. Crosslinking of the 
BAFF receptor activates the NF-κB pathway non-canonically via NF-κB-inducing kinase 
(NIK) and inhibitor of NF-κB, IκB kinase 1 (ref. 14). Although BAFF receptor signalling 
was first believed to be independent of BCR signalling, a recent report suggested that BAFF 
receptor signalling may also include the BCR signalling pathway components15. The NF-κB 
pathway substantially contributes to B-cell survival by inducing the expression of Bcl-2, Bcl-
xL and Mcl-1 (ref. 13). 
The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a 
member of the carcinoembryonic antigen and the immunoglobulin families, is engaged in 
intercellular binding interactions that affect various signal transduction pathways associated 
with cell proliferation and differentiation16,17. CEACAM1 usually acts via intercellular 
 
 
  59 
 
adhesion through homophilic (CEACAM1–CEACAM1) or heterophilic (CEACAM1–
CEACAM5, CEACAM1–CEACAM6 and CEACAM1–CEACAM8) interactions17,18. In 
mice, there are at least four CEACAM1 isoforms: CEACAM1-4L, CEACAM1-4S, 
CEACAM1-2L and CEACAM1-2S. The CEACAM1 ectodomain is composed of four 
(CEACAM1–4) or two (CEACAM1–2) highly glycosylated Ig-like domains, which are 
highly flexible and participate in anti-parallel (trans) and parallel (cis) homophilic binding19. 
The isoform with the short cytoplasmic tail (CEACAM1-S) can bind calmodulin, 
tropomyosin, actin, annexin II and PDIP38, and is phosphorylated on Ser449 through protein 
kinase C20–22. The isoform with the long cytoplasmic tail (CEACAM1-L) contains two 
additional immunoreceptor tyrosine-based inhibitory motif-carrying segments17,23. Within 
these immunoreceptor tyrosine-based inhibitory motif-carrying segments, phosphorylation at 
two tyrosines initiates signalling through CEACAM1-mediated signal transduction. 
Furthermore, trans-homophilic CEACAM1 binding induces cis-dimerization, and primarily 
dimeric but not monomeric CEACAM1-L recruits two specific Src homology region 2 
domain-containing phosphatase-type phosphatases (PTPN6 and PTPN11)19,24–26. 
Crosslinking of CEACAM1 as monomers and dimers induces binding of the SRC family of 
PTK members to CEACAM1, which typically causes cell activation19,26. 
CEACAM1 is expressed by a broad range of cell types, including angiogenically 
activated endothelia/lymphendothelia, various leukocyte subpopulations, normal epithelial 
cells and tumour cells16. Although Ceacam1–/– mice do not exhibit this broad CEACAM1 
expression, they develop normally and, in the absence of specific challenges, show no signs 
of disease27. CEACAM1 has been described primarily as a regulator of T cells in the gut20,28–
30. Expression of CEACAM1-L inhibits T-cell proliferation and therefore prevents 
inflammatory bowel disease30. Expression of CEACAM1-S is essential for the development 
of follicular T helper cell-driven IgA production by gut B cells20. CEACAM1 also acts as a 
co-stimulatory molecule for T-cell receptor and BCR signalling31–33. The role of CEACAM1 
in B-cell homeostasis and in antiviral B-cell responses in vivo remains unknown. 
 We report here that CEACAM1 is expressed on blood, bone marrow, lymph node, as 
well as splenic MZ and follicular zone (FO) B-cell subpopulations in mice. In vitro 
CEACAM1 expression induces the survival of proliferating B cells. In line with this finding, 
Ceacam1–/– mice carry reduced numbers of total B cells and virtually no MZ B cells. During 
viral infection, the absence of CEACAM1 on B cells leads to an insufficient antiviral B-cell 
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response, and Ceacam1–/– mice die early after infection with the cytopathic vesicular 
stomatitis virus (VSV). 
3.3   Results 
 3.3.1 CEACAM1 is expressed on B-cell subsets. 
 We first analysed CEACAM1 expression on various cell populations in the peripheral 
blood of wild-type (WT) mice. Erythrocytes stained negative for CEACAM1 
(Supplementary Fig. 1). As previously reported34–36, high levels of CEACAM1 expression 
were detected on blood granulocytes (Ly6G+) and monocytes (CD115+) with the anti-
CEACAM1-specific monoclonal antibody (clone CC1, Fig. 1a). Cells from Ceacam1–/– mice 
stained negative for CEACAM1 (Fig. 1a). Next, we analysed CEACAM1 expression on 
lymphoid cells in the blood. CD90.2 cells, representing primarily T cells, showed weak 
CEACAM1 expression by individual cells (Fig. 1b), a finding suggesting that various T-cell 
subpopulations may differentially express CEACAM1. B cells in peripheral blood expressed 
CEACAM1 at high levels (Fig. 1b). Evaluation of precursor (B220+ CD43– IgM+ IgDlow) and 
mature B cells (B220+ CD43– IgDhigh) in the bone marrow revealed strong CEACAM1 
expression in the B-cell lineage (Fig. 1c). In line with this finding, lymph node B cells, 
follicular B cells (FO, B220+ CD19+ CD21/35low CD23hi) and MZ B cells (B220+ CD19+ 
CD21/35hi CD23low) in the spleen expressed CEACAM1 at high levels (Fig. 1d,e). 
Furthermore, quantitative RT–PCR analyses of expression of long and short isoforms of 
CEACAM1 showed that murine splenic B cells express more long than short isoforms (Fig. 
1f). In conclusion, strong CEACAM1 expression was detected in all B-cell subpopulations 
tested, a finding implying that CEACAM1 is functionally relevant in B cells. 
 
 3.3.2 CEACAM1 induces survival genes via Syk and Erk and NF-κB. 
Recently, expression of CEACAM1 in granulocytes was shown to lead to Syk 
phosphorylation37. In addition, expression of CEACAM1 participates in Btk 
phosphorylation38. In B cells, Syk and Btk are essential signalling molecules, which are 
phosphorylated after BCR or BAFFR crosslinkage and play an essential role in induction of 
survival signals15,39. We thus focused on the influence of CEACAM1 on Syk activity during 
CEACAM1 and BCR crosslinkage. Indeed, in B-cell lymphoma immunoprecipitation of 
CEACAM1 pulled down Syk (Supplementary Fig. 2), which confirms the recently 
published interaction of Syk and CEACAM1 (ref. 37). To get insights into the functional 
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relevance of CEACAM1 in B cells, we isolated splenocytes from WT and Ceacam1–/–  mice 
and challenged them with anti-IgM, anti-CEACAM1 activating antibody (monoclonal 
antibody, CC1) or lipopolysaccharide (LPS). Ig-α, which associated with BCR, showed slight 
tyrosine-phosphorylation after IgM crosslinkage (Fig. 2a, left panel). Neither anti-
CEACAM1 monoclonal antibody challenge nor LPS treatment induced phosphorylation of 
Ig-α (Fig. 2a, right panel). We subsequently analysed Syk tyrosine phosphorylation in WT 
and Ceacam1–/–  mice. As expected BCR crosslinkage induced strong Syk phosphorylation. 
Absence of CEACAM1 strongly reduced Syk phosphorylation after BCR crosslinkage (Fig. 
2b, left panel). Challenge with anti-CEACAM1 monoclonal antibody also triggered 
phosphorylation of Syk, which was stronger than LPS-induced Syk phosphorylation (Fig. 2b, 
right panel). Therefore, we concluded that CEACAM1 enhances Syk phosphorylation not 
only directly, but also after BCR crosslinkage. Next we analysed the downstream target of 
Syk, Btk, another member of the Tec family of non-transmembrane PTKs. Flow cytometric 
analysis showed that Btk is transiently phosphorylated in B cells derived from WT but not in 
Ceacam1–/–  mice after challenge with anti-IgM (Fig. 2c, upper panel) antibody. Similarly, 
anti-CEACAM1 monoclonal antibody challenge induced Btk phosphorylation in WT B cells 
(Fig. 2c, lower panel). We therefore conclude that CEACAM1 directly influences the 
phosphorylation of Syk and Btk, after BCR and CEACAM1 crosslinkage. To gain insight 
into downstream targets of CEACAM1 activation, we analysed specific Syk substrates. We 
observed that the CEACAM1 signal phosphorylate Erk1 (Erk-42) but not Erk2 (Erk-44) and, 
to a lesser extent, p-38. LPS could phosphorylate both Erk1/2 and p-38 (Fig. 2d,e). 
Triggering with the anti-CEACAM1 monoclonal antibody induced degradation of IκBα and 
slight phosphorylation of p65, a finding suggesting that CEACAM1 signals activate the 
canonical NF-κB pathway (Fig. 2f). 
 Tonic BCR signalling followed by Syk phosphorylation induces several survival 
genes, which are essential for B cell survival12. To see whether lack of CEACAM1 
influences expression of those genes, we cultured purified splenic B cells from WT and 
Ceacam1–/–  mice for 24 h without further stimulation and measured mRNA expression of 
various NF-κB-regulated genes. Indeed, lack of CEACAM1 led to reduced expression of 
Bcl6, Pax5, Bcl2a1 and Xiap (Fig. 2g). In line with the known positive feedback loop of NF-
κB, we found reduced expression of NF-κB p65, Rel-B, Nfatc1 and Nfatc2 in Ceacam1–/–  B 
cells (Fig. 2h,i). c-Jun, c-Fos and Ap1 were not influenced by CEACAM1 expression (Fig. 
2j). Blimp1, which is another key regulator of plasma cell differentiation, was not affected by 
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CEACAM1 expression (Fig. 2k). Taken together, we found that CEACAM1 contributed to 
the Syk phosphorylation during BCR and/or CEACAM1 crosslinkage, leading to the 
enhanced expression of NF-κB, NFAT and survival genes. 
 
 3.3.3 CEACAM1 promotes survival of B cells in vitro. 
We found that expression of CEACAM1 enhanced BCR-dependent Syk 
phosphorylation. Therefore, absence of CEACAM1 reduced expression of survival genes, 
which are induced via the tonic BCR signal. To see how lack of CEACAM1 influenced 
proliferation and survival of B cells, we labelled WT and Ceacam1–/– B cells with 
carboxyfluorescein succinimidyl ester (CFSE) and challenged them with anti-CEACAM1 
monoclonal antibody or the BCR-independent B-cell activator such as LPS, or CD40 ligand 
(CD40L) in combination with mouse interleukin (IL)-4. Challenge with anti-CEACAM1 
(monoclonal antibody, CC1) induced some proliferation in WT but not in Ceacam1–/– B cells 
(Fig. 3a). Challenge with LPS (TLR4-ligand) or CD40/IL-4 induced proliferation that was 
comparable between WT and Ceacam1–/– B cells (Fig. 3a). Therefore, we conclude that the 
induction of proliferation via TLR4 or CD40 is not affected by CEACAM1. 
 Next, we analysed the impact of CEACAM1 on B-cell survival. First, we quantified 
the total number of living B cells with diamidino-2-phenylindole (DAPI) staining and 
fluorescenceactivated cell sorting (FACS) beads. Without any further challenge, WT B cells 
consistently died under our in vitro culture conditions (Fig. 3b), a finding that agrees with 
that of a previous study40. Lack of CEACAM1 enhanced death of B cells (Fig. 3b). When 
challenged with CD40/IL-4, the numbers of WT B cells were higher than those of non-
activated B cells after 24 h (Fig. 3b). The numbers of Ceacam1–/– B cells 24 h after 
stimulation with CD40/IL-4 increased similarly to those of WT B cells, however, declined 
rapidly 24 h after challenge with CD40/IL-4 (Fig. 3b). This rapid decrease was probably due 
to apoptosis and cell death, because Annexin-V staining was significantly enhanced in none 
activated and activated DAPI–, B cells (Fig. 3c). We postulate that defective survival of 
Ceacam1–/– B cells was due to limited Syk and Btk phosphorylation. To test this hypothesis, 
we treated WT and Ceacam1–/– B cells with the Btk inhibitor Ibrutinib41. We observed that 
inhibition of Btk in WT B cells led to the rapid death of B cells. This effect was less 
pronounced in Ceacam1–/– B cells (Fig. 3d). In conclusion, we found that lack of CEACAM1 
signal limited survival of resting and activated B cells. 
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 3.3.4 CEACAM1 promotes B-cell differentiation and survival in vivo. 
We found that CEACAM1 is expressed on all B-cell subpopulations analysed and 
that it influences the survival of B cells, especially after activation. During maturation, 
several activating stimuli allow B cells to progress through various stages (Fig. 4a). To 
determine the influence of CEACAM1 on survival during B-cell proliferation, we analysed 
B-cell subsets in bone marrow, peripheral blood, lymph node and spleen of WT and 
Ceacam1–/– mice. We found that B-cell precursor subsets in the bone marrow are reduced 
only in stages B, C and C’ (Fig. 4b). However, after stage C’ they expand more rapidly; 
therefore, the numbers of newly formed B cells in stages D and E are similar in WT and 
Ceacam1–/– mice (Fig. 4b). This finding is concordant with the similar numbers of newly 
formed (immature, B220+ IgM+) B cells in the peripheral blood (Fig. 4c). These findings are 
also in line with previously published experiments showing that there is no difference in B-
cell numbers in the peripheral blood of Ceacam1–/– mice27. Therefore, we conclude that the 
generation of newly formed B cells is hardly affected by CEACAM1. B-cell analysis in the 
peritoneal cavity showed that the frequency of B2 (CD19+ B220+ CD43–) B cells was slightly 
reduced. B1a (CD19+ B220+ CD43+ CD5+) B-cell frequency was significantly reduced, 
whereas the B1b (CD19+ B220+ CD43+ CD5–) B-cell population was higher in Ceacam1–/– 
mice (Supplementary Fig. 4). 
Next, we examined whether CEACAM1 signals are essential for B cells in secondary 
lymphoid organs, where newly formed B cells undergo further proliferation and 
differentiation. In lymph nodes, the numbers of newly formed (CD19+ IgM+ IgDlow) B cells in 
WT and Ceacam1–/–  mice were similar (Fig. 4d). In contrast, the numbers of matured (M, 
CD19+ IgDhigh) B cells were significantly reduced in the lymph nodes of Ceacam1–/–  mice 
(Fig. 4d). In the spleen, the T1, T2 and T3 populations of transitional B cells were reduced in 
the absence of CEACAM1 (Fig. 4e). The numbers of follicular B cells I (Fol I) and II (Fol 
II), MZ precursor cells and MZ B cells were dramatically reduced in the spleen of   
Ceacam1–/–  mice (Fig. 4e). In line with this finding, the numbers of mature B cells (stage F, 
B220+ CD43– IgDhigh) in the bone marrow were reduced in Ceacam1–/–  mice (Fig. 4b). 
Similarly, histologic analysis showed lower numbers of B cells in the spleen and lymph node 
(Fig. 4f) and the absence of MZ B cells as well as low numbers of metallophilic (CD169+) 
macrophages in Ceacam1–/–  mice (Fig. 4g). To strengthen our hypothesis that reduced Syk 
phosphorylation after B-cell-activating factor receptor (BAFFR) or BCR activation, but not 
TLR or Fcgr2b signalling, is responsible for reduced B-cell numbers in Ceacam1–/–  mice, we 
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performed histology of Jh–/–, Baffr–/–, Fcgr2b–/– and Myd88/Trif–/– mice. Histological analysis 
showed that a lack of BCR and BAFFR signalling, but neither TLR nor Fcgr2b signalling, 
reproduces the B-cell deficiency seen in Ceacam1–/– mice (Supplementary Fig. 5). 
 Next, we determined whether defective intrinsic survival signals are responsible for 
reduced B-cell numbers in Ceacam1–/– B cells, we transferred the same number of B cells 
from WT or Ceacam1–/– mice into B-cell-deficient (Jh–/–) mice. Adoptively transferred WT B 
cells survived in the Jh–/– mice and repopulated the spleen within 30 days (Fig. 4h). In 
contrast, Ceacam1–/– B cells were not detectable after 30 days (Fig. 4h), a finding suggesting 
that the absence of intrinsic CEACAM1 limits the survival of B cells after proliferation in Jh–
/– mice. To gauge the direct influence of CEACAM1 expressed on B cells, we made use of 
mixed bone marrow chimeras, where the irradiation of WT (CD45.2) mice was followed by 
reconstitution with bone marrow from WT (CD45.1) and WT (CD45.2, mixed 1:1) or WT 
(CD45.1) and Ceacam1–/– (CD45.2, mixed 1:1) mice. Analysis of peripheral blood showed 
some, but not statistically significant difference in blood B-cell levels between WT and 
Ceacam1–/– cells (Fig. 4i). In contrast, splenic MZ B cells were only derived from WT 
(CD45.1) mice (Fig. 4j). FO B cells were also mainly from WT (CD45.1) origin (Fig. 4j). 
This suggests that CEACAM1 B-cell intrinsic signals are essential for B-cell survival after B 
cells home to the spleen. Next, we analysed how the lack of CEACAM1 contributes to 
antibody production in unchallenged mice. Analysis of various immunoglobulin (Ig) 
subtypes in the serum of naïve WT and Ceacam1–/– mice showed a reduction in IgM, IgG1, 
IgG2a, IgG2b, IgG3, IgA and IgE in Ceacam1–/– mice (Supplementary Fig. 6). In 
conclusion, CEACAM1 expression influences survival in mature B cells. 
 
 3.3.5 CEACAM1 ensures mouse survival during VSV challenge. 
Next, we analysed the role of CEACAM1 during antigen challenge. We infected mice 
with VSV, a cytopathic pathogen for which systemic control strongly depends on the rapid 
induction of neutralizing antibodies42. We found strong expression of CEACAM1 in the MZ 
(Fig. 5a), a site at which VSV-specific B cells become activated43,44. Because CEACAM1 is 
a natural CEACAM1 ligand, this finding suggests that CEACAM1 may release an important 
survival signal during antigenic challenge. To determine the role of CEACAM1 during B-
cell activation, we transferred same number of B cells from Vi10 mice (WT × Vi10), which 
express a VSV-specific BCR or from Vi10 mice crossed to Ceacam1–/– mice (Ceacam1–/– × 
Vi10), into WT mice and infected them with VSV. After 3 days, the number of WT × Vi10 B 
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cells but not Ceacam1–/– × Vi10 B cells was expanded (Fig. 5b). In the absence of 
stimulation, Ceacam1–/– × Vi10 B cells were reduced as compared to WT × Vi10 B cells 
(Fig. 5b), a finding indicating that CEACAM1 provides an important survival signal in 
antigen-activated and non-activated B cells. In line with these data, Ceacam1–/– mice 
displayed delayed induction of total VSV-neutralizing antibodies (Fig. 5c, left panel). In 
agreement with this finding, Ceacam1–/– mice failed to generate neutralizing IgG antibodies 
(Fig. 5c, right panel). ELISA confirmed that VSV-specific IgG levels were significantly low 
in Ceacam1–/– mice (Supplementary Fig. 7, right panel). Notably, anti-VSV IgM levels 
were significantly reduced in Ceacam1–/– mice (Supplementary Fig. 7, left panel). During 
challenge with non-replicating ultraviolet-inactivated VSV, Ceacam1–/– mice did not secrete 
neutralizing antibodies (Fig. 5d), a finding suggesting that Ceacam1–/– mice exhibit strongly 
impaired B-cell functions. To demonstrate that CEACAM1 expression by B cells is 
responsible for poor VSV neutralizing antibody responses, we adoptively transferred 
CEACAM1-competent VSV-specific B cells into WT and Ceacam1–/– mice. This adoptive 
transfer of B cells rescued VSV-neutralizing antibody responses (Fig. 5e). Detailed analysis 
showed that both MZ and FO B cells could rescue the VSV neutralizing antibody response in 
the Ceacam1–/– mice (Supplementary Fig. 8). Absence of early neutralizing antibodies can 
result in the spread of VSV to the nervous system45. To determine whether a reduction in the 
levels of neutralizing antibodies in Ceacam1–/– mice affected the immune response of virus 
control, we analysed organ virus titres 8 days after systemic VSV infection. Indeed, 
Ceacam1–/– mice exhibited VSV replication in the brain and spinal cord, whereas WT mice 
controlled VSV replication in all organs (Fig. 5f). VSV replication in Ceacam1–/– brains was 
associated with the death of mice (Fig. 5g). To determine whether a diminished B-cell 
response contributed to mortality, we performed survival experiments. Ceacam1–/– mice with 
adoptively transferred VSV-specific WT B cells survived VSV infection (Fig. 5h). 
Therefore, B-cell intrinsic expression of CEACAM1 is essential for initiating a protective 
antiviral immune response after exposure to VSV. 
 
3.3.6 CEACAM1 facilitates LCMV-dependent B-cell activation. 
Next, we infected WT and Ceacam1–/– mice with non-cytopathic lymphocytic 
choriomeningitis virus (LCMV) to confirm whether antigen-specific B-cell responses are 
impaired in Ceacam1–/– mice. Early control of an infection dose of 200 plaque-forming units 
(PFUs) of LCMV depends only on CD8+ T cells. However, at higher infection doses, B cells 
 
 
  66 
 
are important for LCMV control46. WT mice produce higher titres of LCMV-specific 
antibodies than do Ceacam1–/– mice during LCMV infection (Fig. 6a). In line with this 
finding, LCMV replication in the liver of Ceacam1–/– mice was prolonged (Fig. 6b). 
 
 3.3.7 Human B-cell subpopulations express CEACAM1. 
To determine whether CEACAM1 also plays a potential role in human B cells, we 
measured CEACAM1 expression by naïve B cells. Previous publications reported that most 
B cells isolated from peripheral blood express CEACAM1 (ref. 32). Also, we found that 
naive human B cells (IgDhigh CD27–) and memory B cells (CD27+) express substantial levels 
of CEACAM1 (Fig. 7a). The expression of memory B cells is slightly higher than that of 
naïve B cells (Fig. 7b), a finding suggesting that the CEACAM1 signal in humans may be 
crucial for the survival of memory B cells rather than naïve B cells. 
 
3.4  Discussion 
The results of this study demonstrate that CEACAM1 expression is essential for the 
survival of murine B cells. The absence of CEACAM1 expression on murine B cells is 
associated with reduced numbers of B cells and a defective immune response after viral 
antigen challenge. 
Greicius et al.31 demonstrated that binding of CEACAM1 with an anti-CEACAM1 
monoclonal antibody induces strong B-cell proliferation. Other studies showed that BCR 
activation in the presence of another anti-CEACAM1 monoclonal antibody (clone T84.1) 
limits B-cell proliferation47,48. In the current study, we demonstrate that CEACAM1 
crosslinkage had some effect on proliferation. However, in vitro and in vivo we found a 
strong influence of CEACAM1 on the survival of activated B cells. Therefore, we consider 
that a prolonged signal via CEACAM1 ligation is essential for promoting survival signals 
and maintaining B-cell numbers, which could explain reduced B-cell numbers in Ceacam1–/– 
mice. 
 BCR crosslinking by auto-antigens has an essential role in the differentiation of 
transitional B cells into MZ B cells and follicular B cells6. In addition, this tonic BCR signal, 
together with constant signalling via the BAFF receptor, is the most important survival signal 
for naïve B cells. How this diverse process can be regulated by BCR signals remains 
unexplained. We suggest that CEACAM1 is another strong regulator of B-cell survival. This 
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is supported by previous findings that CEACAM1 regulates apoptosis in granulocytes49. 
Because CEACAM1 is expressed most strongly by B cells, and because CEACAM1 is its 
own ligand, we suggest that CEACAM1 induces positive survival signals primarily on B 
cells within the B-cell follicles and that CEACAM1 acts as a positive feedback loop once B 
cells reach the B-cell follicle. Therefore, in addition to chemokine gradients50, CEACAM1 
expression appears to contribute to the generation of B-cell follicles. 
 We found that Syk phosphorylation after BCR crosslinkage was dependent on 
expression of CEACAM1. In line with these results, monoclonal antibody activation of 
CEACAM1 led to Syk phosphorylation. These data suggest that CEACAM1 directly 
interacts with BCR signalling and therefore would influence the tonic BCR signal as well as 
antigen-dependent BCR activation. Tonic BCR signalling, but also BAFFR signalling, 
induces several survival genes via Syk. Therefore, lack of BCR and BAFFR signalling limits 
B-cell development and survival. Indeed, in line with data from Jh–/– or Baffr–/– mice, 
Ceacam1–/– mice showed strongly reduced B-cell numbers in naïve mice. Therefore, we 
concluded that CEACAM1, in addition to BAFFR, is another important membrane molecule 
influencing BCR signalling via Syk. 
 We found that CEACAM1 activation leads to Btk phosphorylation. This finding is 
related to the enhanced survival of B cells. Loss-of-function mutations in BTK lead to X-
linked agammaglobulinemia because of a complete absence of mature B cells51. Mice 
deficient in CD19 or BCR exhibit a strongly reduced number of mature B cells52. This 
reduction in the numbers of MZ B cells in CEACAM1-deficient mice is also found in mice 
and humans lacking the Wiskott-Aldrich syndrome protein (WASp)53. WASp is also 
involved in BTK phosphorylation54. As we have shown for CEACAM1, the necessity for 
WASp in the generation of the MZ B-cell compartment is B-cell intrinsic55. Whether 
CEACAM1 affects WASP function must be investigated in future studies. 
 We found that CEACAM1 is expressed on human B cells. This could suggest that 
also in human antiviral immune response, CEACAM1 signalling may play a role in inducing 
sufficient antibody responses against different viruses. Therefore, we would suggest that lack 
of CEACAM1 could be another factor explaining B-cell deficiency in humans. If indeed 
CEACAM1 deficiency occurs in humans, remains to be fully elucidated. 
 Recently, we found that CD169+ macrophages enforce viral replication and therefore 
are essential for initiating an antiviral immune response44,56. B cells play an important role in 
recruiting CD169+ macrophages3. Therefore, B-cell deficiency leads to defects in enforced 
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virus replication (Supplementary Fig. 9) and a reduction in the innate immune response. 
Indeed, we found that in Ceacam1–/– mice the ability of CD169+ macrophages to enforce 
virus replication was impaired (Supplementary Fig. 10). Which could be an additional 
mechanism how CEACAM1 deficiency in B cells contributes to defective anti-VSV immune 
response. 
 In conclusion, we found that CEACAM1 expressed on murine B cells is an important 
regulator of B-cell homeostasis. During exposure with cytopathic virus, CEACAM1 was 
essential for inducing an efficient antiviral antibody response and thereby reducing mouse 
mortality. 
 
3.5  Methods 
 3.5.1 Mice  
 All mice used in this study, including Ceacam1–/–, Jh–/–, Tcrab–/–, Aid–/–, sIgM–/–, 
Myd88/Trif–/–, Baffr–/– and Fcgr2b–/– mice, were maintained on the C57BL/6 genetic 
background (back-crossed at least 8 times and as many as 16 times) and were bred as 
homozygotes. Vi10/CD45.1 mice expressing VSV-specific BCR as a transgene were used for 
cell transfer studies, and mice expressing the CD45.1 transgene were used for reconstitution 
of bone marrow. Six to eight-week-old, age- and sex-matched mice were used for all the 
studies. All animals were housed in single ventilated cages. During survival experiments, the 
health status of the mice was checked twice daily. Animal experiments were authorized by 
the Nordrhein Westfalen Landesamt für Natur, Umwelt und Verbraucherschutz 
(Recklinghausen, Germany), and in accordance with the German law for animal protection or 
according to institutional guidelines at the Ontario Cancer Institute of the University Health 
Network and at McGill University. Animals exhibiting severe symptoms of sickness or 
paralysis or showing substantial weight loss during VSV infection were put to death and 
were considered dead for statistical analysis. 
 
 3.5.2 Bone marrow chimeras 
For generation of bone marrow chimeras, C57BL/6 mice were irradiated twice for 
7min each with a total of 1,050 rad. After 24 h, mice were reconstituted intravenously with   
5 × 106 bone marrow cells from each donor for mixed bone marrow chimeras. Mice were 
analysed 40–45 days after reconstitution. 
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 3.5.3 Virus and plaque assays 
 VSV, Indiana strain (VSV-IND, Mudd-Summers isolate), was originally obtained 
from Professor D. Kolakofsky (University of Geneva, Switzerland). Virus was propagated on 
BHK-21 cells at a multiplicity of infection of 0.01. VSV concentration was determined as 
described below, and was then plaque purified on Vero cells57. Mice were infected 
intravenously with VSV at the indicated doses. Virus titres were measured with a plaque-
forming assay. For this assay, organs were smashed in Dulbecco’s modified Eagle medium 
(DMEM) containing 2% fetal calf serum (FCS), titrated 1:3 over 12 steps, and plaqued on 
Vero cells. After a 2-h incubation at 37 ºC, overlay was added, and the virus preparation was 
again incubated at 37 ºC. Plaques were counted 24 h later by the use of crystal violet staining. 
The LCMV strain WE was originally obtained from F. Lehmann-Grube (Heinrich Pette 
Institute, Hamburg, Germany) and was propagated on L929 cells, MC57 cells or both. Mice 
were infected intravenously at the indicated dose. LCMV viral titres were detected by a 
plaque-forming assay on MC57 fibroblasts as previously described58. In short, smashed 
organs were plaqued with MC57 cells as described above and incubated at 37 ºC. After a 3-h 
incubation at 37 ºC, overlay was added, and the virus preparation was again incubated at     
37 ºC. Plaques were counted 72 h later by LCMV NP staining. Cells were fixed (with 4% 
formaldehyde solution), permeabilized (with 1% Triton-X solution), blocked (with 10% FCS 
in phosphate-buffered saline) and stained with anti-LCMV NP antibody (made in house). 
ECL-conjugated anti-rabbit-IgG antibody was used as a secondary antibody. Plaques were 
detected by colour reaction (0.2M Na2HPO4 + 0.1M citric acid + 30% H2O2 +                       
o-phenylenediamine dihydrochloride), all chemicals from Sigma-Aldrich. 
 
 3.5.4 Neutralizing antibody assay 
Serum was prediluted (1:40). The complement system was inactivated at 56 ºC for 30 
min. For analysis of IgG kinetics, diluted samples were treated with 2-mercaptoethanol (0.1 
M) for removal of IgM. Serum was titrated 1:2 over 12 steps and was incubated with 1 × 103 
PFU of VSV. After a 90-min incubation at 37 ºC, the virus–serum mixture was plaqued onto 
Vero cells. Overlay was added after 1 h, and the mixture was incubated again for 24 h at 37 
ºC. Plaques were counted by crystal violet staining. Antibody titres are presented as two- or 
threefold dilution steps ( ̶ log2 and  ̶ log3) times the predilution (that is, × 40). 
 
 
 
 
  70 
 
 3.5.5 B-cell culture 
 Spleens retrieved from WT and Ceacam1–/– mice were homogenized in magnetic-
activated cell sorting (MACS) buffer (1% FCS and 0.8% 0.5M EDTA). B220+ B cells were 
isolated by positive selection with CD45R-conjugated magnetic beads (MACS Miltenyi 
Biotech). Flow cytometry confirmed that the purity of B220+ cells was higher than 95%. For 
proliferation assays, cells were labelled with 5 mM carboxyfluorescein succinimidyl ester, 
and 2 × 105 cells per well were cultured in 96-well flat bottom plates in RPMI 1640 medium 
supplemented with 10% LPS-free FCS, 1% antibiotics and 0.1% 50mM 2-mercaptoethanol. 
They were then challenged with anti-CEACAM1 (20 µg ml ̶ 1, clone CC1; a kind gift from 
Dr Kathryn V. Holmes, University of Colorado, Denver, CO) antibody or recombinant 
mouse CD40 ligand (1 µg ml ̶ 1) in combination with mouse IL-4 (10 ng ml ̶ 1; R&D Systems) 
or LPS (100 ng ml ̶ 1; Sigma-Aldrich) for 48 h. Similarly, for inhibition experiments, purified 
B cells (as described above) were cultured in the medium described above with recombinant 
mouse CD40 ligand (1 µg ml ̶ 1) in combination with mouse IL-4 (10 ng ml ̶ 1; R&D Systems) 
and were treated with 10 mM Ibrutinib (Selleck). Control wells were supplemented with 
equal amounts of DMSO used to dissolve Ibrutinib. Cell death was measured by DAPI (Life 
Technologies) staining. For survival experiments, B cells were cultured as mentioned above, 
and cells were stained with Annexin-V (BD Biosciences) followed by DAPI. Proliferation 
and survival were determined by FACS at indicated time points. For cell signalling 
experiments, splenocytes were dissociated in VLE-DMEM supplemented with 10% LPS-free 
FCS and 1% antibiotics and were challenged with anti-CEACAM1 (clone CC1, 20 µg ml ̶ 1; 
K. Holmes) and anti-IgM (10 µg ml ̶ 1) antibody (Jackson ImmunoResearch Laboratories, 
Inc.) for various time periods at 37 ºC. 
 
 3.5.6 Histology 
Histologic analyses of snap-frozen tissue were performed with a monoclonal antibody 
to VSV glycoprotein (Vi10; made in-house). Anti-CD45R (B220; RA3-6B2), anti-CD90.2 
(53-2.1), anti-CD19 (1D3), anti-CD1d (1B1) and anti-CEACAM1 (CC1) monoclonal 
antibodies were purchased from eBioscience. Biotin-anti-CD169/SIGLEC1 (MOMA-1) was 
purchased from Acris. Sections were washed and stained with streptavidin (eBioscience). In 
short, sections were fixed with acetone, and nonspecific antigens were blocked in PBS 
containing 2% FCS for 15 min, followed by various stainings of antibodies, diluted 1:100 in 
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blocking solution for 45 min. Images of stained sections were acquired with a fluorescence 
microscope (KEYENCE BZ II analyzer). 
 
 3.5.7 Flow cytometry 
Peripheral blood cells were stained with anti-Ly6G (RB6-8C5), anti-CD115 (AFS98), 
anti-CD45R (B220; RA3-6B2), anti-CD90.2 (30-H12), anti-CEACAM1 (CC1; with 
corresponding isotype control anti-IgG1 (M1-14D12)), anti-IgD (11-26c), anti-CD93 
(AA4.1), anti-CD19 (1D3) (all from eBioscience) and anti-IgM (II/41; BD Biosciences) 
antibodies. Recovered bone marrow cells were resuspended in FACS buffer (0.5M EDTA, 
0.1% sodium azide, 1% FCS in PBS) and incubated with anti-CD45R (B220; RA3-6B2), 
anti-IgD (11-26c), anti-IgM (II- 41), anti-CEACAM1 (CC1), anti CD24 (M1/69; all from 
eBioscience), anti-CD43 (1B-11), and anti-BP1 (6C3; from BioLegend) antibodies. Inguinal 
lymph nodes were disaggregated in FACS buffer, and cells were stained for anti-CD45R 
(B220; RA3-6B2), anti-CD19 (1D3), anti-IgD (11-26c; all from eBioscience), and anti-IgM 
(II/41; BD Biosciences) antibodies. Spleens were dissociated in FACS buffer, and 
splenocytes were incubated with anti-CD45R (B220; RA3-6B2), anti-CD19 (1D3), anti-
CD93 (AA4.1), anti-CD21/35 (8D9), anti-CD23 (B3B4), anti-IgD (11-26c), anti-CEACAM1 
(CC1), anti-CD45.1 (A20), anti-CD45.2 (104; all from eBioscience) and anti-IgM (II/41; 
BD) antibodies. Human peripheral blood samples were stained with anti-IgD (IA6-2) and 
anti-CD27 (M-T271) antibodies (both from BD Biosciences) and anti-CEACAM1 
(monoclonal antibody, B3-17) antibody (from Dr Singer, Essen). Peritoneal B cells were 
stained for anti-CD19 (1D3), anti-CD45R (B220; RA3-6B2), anti-IgM (II/41; all from 
eBioscience), and anti-CD5 (53-7.3; BD Biosciences) and anti-CD43 (1B-11; from 
BioLegend) antibodies. Dead cells were discriminated by staining with propidium iodide (PI, 
eBioscience) and/or DAPI and were excluded from all analyses except for blood. For cell 
signalling experiments, cells were fixed and permeabilized according to the manufacturer’s 
instructions (BD Phosflow, BD Biosciences). The cells were stained with anti-Btk 
(pY223)/Itk (pY180) (BD Phosflow) antibody. All antibodies were diluted 1:100 to their 
original concentration in FACS buffer. For quantification of total cell numbers, FACS beads 
were used (BD Biosciences). All stained cells were analysed on an LSRII or a FACS 
Fortessa (BD Biosciences) flow cytometer, and data were analysed with Flowjo software. 
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 3.5.8 Immunobloting 
Spleens were dissociated, and splenocytes were subjected to erythrocyte lysis buffer 
(MORPHISTO). Next, 10 × 106 cells were challenged with or without anti-CEACAM1 
(clone CC1, 20 µg ml ̶ 1) antibodies, anti-IgM (Jackson ImmunoResearch Laboratories, Inc., 
10 µg ml  ̶ 1) antibodies, and LPS (Sigma-Aldrich, 100 ng ml  ̶ 1) treatment for indicated time 
points. Cells were lysed with boiling SDS buffer (1.1% SDS, 11% glycerol, 0.1M Tris; pH 
6.8) with 10% 2-mercaptoethanol. Total cell extracts were examined by 10% SDS–PAGE 
gels and transferred onto Whatman nitrocellulose membrane (GE Healthcare) by standard 
techniques. Membranes were blocked for 1 h in 5% BSA (PAA Laboratories) in TBS 
supplemented with 1% Tween-20 and incubated with the following antibodies: antiphospho- 
Igα (Y182); anti-phospho-Syk/ZAP (Y352/Y319); anti-phospho-p44/42 (p-Erk1/2); anti-
phopshpo-p38; anti-phospho-NF-κB p65; anti-Syk; anti-p44/42 (Erk1/2), anti-p38; anti-IκBα 
(all from Cell Signalling Technologies); anti-Igα (Thermo Scientific); and anti-NF-κB p65 
(Santa Cruz). The secondary antibodies anti-actin (Cell Signalling Technologies) and anti-
GAPDH (Meridian Life Science) were detected by horse radish peroxidase (HRP)-
conjugated anti-mouse IgG (Bio-Rad) or anti-rabit IgG (GE Healthcare) antibodies, or both. 
Signals were detected with the BIO RAD ChemiDoc imaging system and analysed with the 
manufacturer’s software. Blots were quantified with KODAK MI software. Images have 
been cropped for presentation purpose. Full-size images are presented in Supplementary Fig. 
3. 
 
 3.5.9 Immunoprecipitation 
Mouse B-lymphocyte H16-L10-4R5 cells were cultured in RPMI 1660 medium 
supplemented with 10% FCS and 1% antibiotics. 25 × 106 cells were lysed in dulbecco’s 
phosphate-buffered saline (DPBS) supplemented with 1% Triton-X and protease inhibitor 
cocktail (both from Sigma-Aldrich). Lysates were incubated with anti-CEACAM1 antibody 
(CC1, Novus Biologicals, 5 µg ml  ̶ 1) overnight at 4º. CEACAM1 was immunoprecipitated 
with protein G dynabeads (Life technologies). 
 
 3.5.10 RT–PCR 
Total RNA was extracted from MACS-sorted pure B cells with TRIZOL reagent 
(Ambion) according to the manufacturer’s instructions. RNA was transcribed with a 
QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-time PCR amplification of 
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single genes was performed with SYBR Green quantitative PCR master mix in a Light 
Cycler 480 (Roche). QuantiTect Primer assays for Bcl-6, Pax-5, Rel-B, c-Jun, c-Fos, Ap1S1, 
CD5, NFATc1, NFATc2, NF-κB, BCL2A1, XIAP, and Blimp-1 (Qiagen) were used for 
quantification of mRNA expression of the respective genes. The following oligonucleotide 
primers that detect murine CEACAM1 isoforms were used for detection: mouse CEACAM1, 
a common sense primer that detects both long and short isoform FP-5'-
GCCATGCAGCCTCTAACCCACC-3'; and two antisense primers that detect specific 
isoforms, mouse CEACAM1-L BP-5'-CTGGAGGTTGAGGGTTTGTGCTC-3' and mouse 
CEACAM1-S BP-5'-TCAGAAGGAGCCAGACCCGCC-3'. The product was analyzed on 
3% agarose gels in Tris-borate-EDTA buffer and visualized by ethidium bromide staining. 
For analysis, expression levels of target genes were normalized to GAPDH, 18S r-RNA 
(Qiagen), or both as an internal control gene (ΔCt). Gene expression values were then 
calculated with the ΔΔCt method; the mean of 4 untreated WT B cells (0 hours after sorting) 
was used as a calibrator to which all other samples were compared. Relative quantities (RQ) 
were determined with the equation RQ = 2–ΔΔCt. 
 
 3.5.11 LCMV-glycoprotein GP1-specific IgG measurements 
The detection of LCMV glycoprotein GP-1-specific IgG by ELISA has been 
previously described59. In short, 96-well flat-bottom Nunc Immuno Plates (Thermo 
Scientific) were coated with anti-human IgG (Jackson ImmunoResearch Laboratories, Inc.) 
in coating buffer (0.1M Na2CO3 + 0.1M NaHCO3; pH 9.6) overnight at 4 ºC. On the next 
day, plates were washed with washing buffer (PBS with 0.05% Tween-20), and unspecific 
binding was blocked with 2% FCS in PBS for 2 h. Plates were incubated with LCMV Gp-Fc 
supernatant (made in-house) for 3 h at room temperature. Plates were washed and titrated 
with pre-diluted (1: 20) serum over 12 wells with 1:3 dilutions in successive wells. After a 
90-min incubation, plates were incubated with HRP-conjugated anti-mouse-IgG antibody 
(Sigma). After a 1-h incubation, plates were developed as described below. 
 
 3.5.12 ELISA measurements 
For detection of VSV-specific anti-IgG and anti-IgM antibodies, 96-well flat-bottom 
Nunc Immuno Plates (Thermo Scientific) were coated with baculovirus VSV-GP42 in coating 
buffer 0.1M NaCO3 (0.1M Na2CO3 + 0.1M NaHCO3; pH 9.6) overnight at 4 ºC. On the next 
day, plates were washed with washing buffer (PBS with 0.05% Tween-20), and unspecific 
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binding was blocked with 2% FCS in PBS for 1–2 h. Plates were washed once and titrated 
with prediluted (1:15) serum over 12 wells with 1:3 dilutions in successive wells. Plates were 
incubated at room temperature for 2 h. Plates were washed with washing buffer and 
incubated with HRP-conjugated anti-mouse-IgG (Sigma) or anti-mouse-IgM (Sigma) 
antibody for 30–60 min. Plates were washed and incubated with 1× TMB Substrate solution 
(eBioscience) in the dark, after which 10% H2SO4 solution was added to stop the colour 
reaction. Optical density was measured at 450 nm (FLUOstar Omega, BMG LABTECH). 
Various immunoglobulin isotypes and subtypes were measured in naïve serum of WT and 
Ceacam1–/– mice as described55. 
 
 3.5.13 Statistical analysis 
Data are expressed as mean ± s.e.m. Student’s t-test was used to detect statistically 
significant differences between groups. Significant differences between several groups were 
detected by one-way analysis of variance (ANOVA) with Bonferroni or Dunnett post hoc 
tests. Survival was compared with log-rank (Mantel-Cox) tests. The level of statistical 
significance was set at P < 0.05. 
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3.8 Figure Legends 
 3.8.1 Figure 1: CEACAM1 is expressed on murine B-cell subsets. 
(a,b) Representative histogram showing CEACAM1 expression in leukocyte subpopulations 
isolated from wild-type (WT, black line) and Ceacam1–/– mice (red line). Isotype control 
antibody staining of leukocytes from WT mice is shown as a grey area. Peripheral blood 
leukocytes gated for Ly6G (granulocytes) and CD115 (monocytes; a) and CD90.2+ (T cells) 
or B220+ (B cells) cells (b), as measured by flow cytometry (n = 6 per group). (c–e) Dot plot 
showing IgD and IgM expression of cells gated on B220, and histogram showing CEACAM1 
expression (black line) versus isotype control antibody staining (grey area) in bone marrow 
(c), lymph nodes (d) and spleens (e), respectively, from WT mice, as measured by flow 
cytometry (n = 6 per group). (f) Representative expression levels of CEACAM1-S and 
CEACAM1-L isoforms in murine splenic B cells by real-time PCR (n = 6). **P<0.01 
(Student’s t-test). Data are representative of two (a–f) experiments (mean±s.e.m., f). 
 
 3.8.2 Figure 2: CEACAM1 in B cells induces survival genes via Syk and Erk and    
   NF-κB. 
(a,b) Representative immunoblot probed with antibodies to phospho-Igα, Igα and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in wild-type (WT) and Ceacam1–/– 
splenocytes (a, left panel) or in WT Splenocytes (a, right panel) or probed with antibodies to 
phospho-Syk, Syk and GAPDH in WT and Ceacam1–/– splenocytes (b, left panel) or in WT 
splenocytes (b, right panel) after treatment with anti-IgM or anti-CEACAM1 monoclonal 
antibody or LPS for indicated time points (n = 4). (c) Representative flow cytometry 
 
 
  76 
 
histogram of WT or Ceacam1–/– splenocytes gated on B cells showing p-Btk (pY223)/Itk 
(pY180) staining; splenocytes were left untreated (grey area) or were treated with anti-IgM 
or anti-CEACAM1 antibody for indicated time points at 37 ºC (n = 3). (d,e) Representative 
immunoblot probed with antibodies to Tyr-P-Erk (p-p44/42 MAPK), Erk (p44/42) and 
GAPDH (d, n = 4) or with antibodies to phospho-p38, p38 and GAPDH (e, n = 3) in WT 
splenocytes after treatment with anti-CEACAM1 antibody or LPS for indicated time points. 
(f) Representative immunoblot and quantification of specific bands after staining for p-NF-
κB p65, NF-κB p65, IκBα and β-actin in WT or Ceacam1–/– B cells after challenge with anti-
CEACAM1 antibody for indicated time points (n = 4). (g–k) RT–PCR analysis of 
representative transcription factors such as Bcl-6, Pax-5 (g, n = 5), Bcl2a1, Xiap (g, n = 7), 
NF- κB p65, Rel-B (h, n = 5–7), Nfatc1, Nfatc2 (i, n = 5) or c-Jun, c-Fos, and Ap1s1 (j, n = 5) 
or Blimp1 (k, n = 7) mRNA from WT and Ceacam1–/– B cells sorted from spleen and 24 h 
after without stimulation (values show fold change to expression in B cells 0 h after sorting). 
*P<0.05; **P<0.01 and ***P<0.001 (Student’s t-test); NS = not significant. Data are 
representative of two (g,h,i,j,k), three (c,e) or four (a,b,d,f) experiments (mean±s.e.m., 
f,g,h,i,j,k). Immunoblot images have been cropped for presentation purpose. Full-size images 
are presented in Supplementary Fig. 3. 
 
3.8.3 Figure 3: CEACAM1 promotes survival of B cells in vitro 
(a) Representative flow cytometry histogram of proliferating B cells from wild-type 
(WT) or Ceacam1–/–  mice that were left untreated (grey area) or were further challenged (red 
line) with anti-CEACAM1 antibody, with LPS, or with recombinant mouse CD40 ligand in 
combination with mouse IL-4 for 48 h, as determined by FACS analysis. Histograms show 
DAPI ̶ cells (n = 6). (b) Absolute numbers of living B cells (DAPI ̶ ) for indicated time points 
(n = 3) sorted from spleen and after challenge with or without recombinant mouse CD40 
ligand in combination with mouse IL-4 (n = 3) determined by FACS analysis. (c) 
Representative histogram and statistical analysis of Annexin-V+ B cells, which were 
stimulated with recombinant mouse CD40 ligand in combination with mouse IL-4 or were 
left unstimulated for 48 h (gated on DAPI ̶  B cells, n = 6). (d) Percentage of DAPI+ B cells 
sorted from spleen of WT and Ceacam1–/–  mice after challenge with recombinant mouse 
CD40 ligand in combination with mouse IL-4 cultured in the presence or absence of Btk 
inhibitor Ibrutinib for 48 h determined by FACS analysis (n = 6). *P<0.05; **P<0.01 and 
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***P<0.001 (Student’s t-test). Data are representative of one of two (b) or two (a,c,d) 
experiments (mean±s.e.m. (b–d)). 
 
 3.8.4 Figure 4: CEACAM1 promotes B-cell survival in vivo. 
(a) Scheme of developmental, maturation and migration stages of B cells in bone 
marrow, blood, lymph node and spleen. Arrows indicate most likely developmental pathway. 
Dotted arrow indicates still debated developmental pathway. Red arrow indicates 
differentiation after antigen challenge. (b–e) Representative dot blots, gating strategy and 
total numbers of B-cell subpopulations from wild-type (WT) and Ceacam1–/– mice as 
measured by flow cytometry in bone marrow (b, n = 6), in blood (c, n = 4), in lymph node (d, 
n = 4) and in spleen (e, n = 10). (f,g) Representative immunofluorescence of spleen and 
lymph node (f, n = 6) sections derived from naïve WT and Ceacam1–/– mice after staining for 
B cells (B220, blue) or T cells (CD90.2, green) and spleen sections stained for marginal zone 
B cells (CD1d, red), follicular B cells (CD19, green), marginal zone macrophages (CD169, 
red) or B cells (B220, blue; g, n = 6). (h) Representative immunofluorescence results of 
spleen sections from Jh–/– mice that were left untreated or were subjected to adoptive 
transference with 1 × 107 B cells derived from WT or Ceacam1–/– mice 30 days before 
analysis, stained for T cells (CD90.2, green) and B cells (CD19, blue; n = 3). (i,j) 
Representative dot blots, gating strategy and statistical analysis of B-cell subpopulations 
from murine bone marrow chimeras reconstituted with 1:1 composition of bone marrow from 
WT(CD45.1): WT(CD45.2) mice in one group and bone marrow from WT(CD45.1): 
Ceacam1–/– (CD45.2) mice in another group after 45 days of reconstitution (n = 5 per group) 
as measured by flow cytometry in blood (i) and spleen (j; only second group has been shown 
for FACS gating strategy). Scale bars, 300 mm. *P<0.05; **P<0.01 and ***P<0.001 
(Student’s t-test); NS = not significant. Data are representative of one (h) or two (b–d,i,j) or 
three (e) experiments (mean±s.e.m., b–e). One representative slide of three (h) or six (f,g) 
slides is shown. 
 
 3.8.5 Figure 5: CEACAM1 ensures mouse survival during VSV challenge. 
(a) Immunofluorescence of spleen sections from naïve wild-type (WT) and  
Ceacam1–/– mice and WT mice 7 h after infection with 2 × 108 PFU of VSV (n = 6), stained 
for VSV glycoprotein (green) and CEACAM1 (red). Scale bars, 300 µm (main image) or 100 
µm (insets). (b) Bar diagram showing percentage of WT × Vi10 and Ceacam1–/– × Vi10 B 
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cells that were adoptively transferred into WT mice (1 × 107 per mouse) on day  ̶ 1 and which 
were infected with 2 × 106 PFU of VSV on day 0. The proliferation was analysed in spleen 3 
days after infection by FACS (n = 3 per group). (c,d) Total VSV-neutralizing antibodies and 
neutralizing IgG antibodies generated in WT and Ceacam1–/– mice after intravenous infection 
with 2 × 106 PFU of VSV (c, n = 6–9 per group) and/or after intravenous infection with 2 
×108 PFU of ultraviolet (UV) light-inactivated VSV (d, n = 8–9 per group). (e) VSV-
neutralizing antibody response and neutralizing IgG antibodies measured in sera of WT and 
Ceacam1–/– mice that also received 1 × 107 VSV-specific B cells (Vi10) on day  ̶ 1 and were 
then intravenously infected with 2 × 106 PFU VSV on day 0 (n = 7–9 per group). (f) VSV 
titres in various organs of WT and Ceacam1–/– mice after intravenous infection with 2 × 106 
PFU of VSV assessed 8 days after infection (n = 6 per group). (g) Survival of WT and 
Ceacam1–/– mice after intravenous infection with 2 × 106 PFU of VSV (n = 9–12 per group). 
(h) Survival of WT and Ceacam1–/– mice that were left untreated or were adoptively given 1 
× 107 VSV-specific B cells (Vi10) on day  ̶ 1 and then intravenously infected with 2 × 106 
PFU of VSV on day 0 (n = 4–9). *P<0.05; **P<0.01 and ***P<0.001 (Student’s t-test for 
b,c,f; Mentel-Cox survival test for g and h). Data are representative of one (b) or two (a,f) or 
three (c–e,h) or four (g) experiments (mean±s.e.m., b,c,f,g). 
 
 3.8.6 Figure 6: CEACAM1 facilitates LCMV-dependent B-cell activation. 
(a)LCMV glycoprotein-specific IgG antibodies measured in sera of wild-type (WT) 
and Ceacam1–/– mice after intravenous infection with 200 PFU of LCMVWE (n = 3–6 per 
group). (b) Liver virus titres of WT and Ceacam1–/– mice 10 days after intravenous infection 
with 2 × 106 PFU of LCMV-WE (n = 3 per group). ***P<0.001 (Student’s t-test). Data are 
representative of one (b) or two (a) experiments (mean±s.e.m., a,b). 
 
 3.8.7 Figure 7: Human B-cell subpopulations express CEACAM1. 
(a) Representative FACS plot and histogram showing CEACAM1(monoclonal 
antibody, B3-17) expression in lymphocyte subpopulations in human peripheral blood on 
naive (IgD+ CD27 ̶ ) and memory (CD27+) B cells. Isotype control antibody staining of 
lymphocytes is shown as red line (n = 6). (b) Histogram plot showing differences in mean 
fluorescence intensity (MFI) levels between human naïve and memory B cells (n = 6). 
*P<0.05 (Student’s t-test). Data are representative of independent staining from six donor 
samples (mean±s.e.m., b). 
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 3.8.8 Supplementary Figure 1: Erythrocytes stain negative for CEACAM1 
Representative dot plot and histogram showing CEACAM1 expression in peripheral 
blood erythrocytes from wild-type (WT, black line) and Ceacam1–/– mice (grey area) as 
measured by flow cytometry (n = 3−4 per group). 
 
 3.8.9 Supplementary Figure 2: CEACAM1 interacts with Syk 
Immunoblot analysis of CEACAM1, Syk and GAPDH in mouse B-lymphocyte from 
whole cell lysate and after immunoprecipitation with or without anti-CEACAM1 antibody 
(mAb, CC1). Data are representative of three independent experiments. 
 
 3.8.10 Supplementary Figure 3: Uncropped western blots shown in Figure 2. 
Proteins were loaded on 10% SDS-PAGE gels and transferred onto Whatman 
nitrocellulose membrane by standard techniques. Nitrocellulose membranes were 
subsequently developed from left to right. 
 
 3.8.11 Supplementary Figure 4: CEACAM1 expression affects B1a B-cell  
   proportion in peritoneum 
a: Representative dot blots, gating strategy, and percentage of B1 B-cell 
subpopulations from wild-type (WT) and Ceacam1–/– mice as measured by flow cytometry in 
peritoneal cavity (n = 5). b: Bar diagram showing average frequencies of indicated subsets 
calculated from the gates shown above. Numbers in plots represents the percentage of events 
as a function of indicated parent gate. B2 (CD19+B220+CD43–), B1a 
(CD19+B220+CD43+CD5+), and B1b (CD19+B220+CD43+CD5–). **P < 0.01; and ***P < 
0.001 (Student’s t-test); ns = not significant. Data are representative of two experiments 
(mean ± SEM). 
 
 3.8.12 Supplementary Figure 5: BAFF receptor signaling resembles CEACAM1- 
   mediated signaling 
Representative immunofluorescence of spleen sections derived from naïve wild-type 
(WT) (n = 6), Myd88/Trif–/– (n = 5), Fcgr2b–/– (n = 6), Baffr–/– (n = 6), and Jh–/– (n = 6) mice 
after staining for marginal zone B cells (CD1d, red), marginal zone macrophages (CD169, 
green), and B cells (B220, blue). Scale bars, 300µm. 
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 3.8.13 Supplementary Figure 6: CEACAM1 influences the levels of serum  
   immunoglobulins  
Histogram showing levels of various serum immunoglobulin isotypes and subtypes in 
naïve wild-type (WT) and Ceacam1–/– mice (n = 8 per genotype). **P < 0.01; and ***P < 
0.001 (Student’s t-test). Data are representative of two experiments (mean ± SEM). 
 
 3.8.14 Supplementary Figure 7: CEACAM1 is essential for anti-VSV-specific Ig  
   production 
Histogram showing anti-VSV–specific IgM and IgG antibodies generated in wild-
type (WT) and Ceacam1–/– mice after intravenous infection with 2 × 106 PFU of VSV (n = 
4−7 per group). *P < 0.05; **P < 0.01; and ***P < 0.001 (Student’s t-test). Data are 
representative of two experiments (mean ± SEM). 
 
 3.8.15 Supplementary Figure 8: MZ and FO B cells can rescue survival in  
   Ceacam1–/– mice   
Histogram showing total VSV neutralizing antibody response (a) and neutralizing 
IgG antibodies (b) measured in sera of wild-type (WT) and Ceacam1–/– mice that also 
received 10 × 106 MZ and 1 × 106 FO VSV-specific B cells (Vi10) on day -1 and were then 
intravenously infected with 2 × 106 PFU VSV on day 0 (n = 3 per group). 
 
 3.8.16 Supplementary Figure 9: B cells but not other cell types are important for  
   the replication of vesicular stomatitis virus in the spleen and the activation  
   of adaptive immunity. 
a: Spleen vesicular stomatitis virus (VSV) titers from wild-type (WT) or Jh–/– mice or 
from WT or Tcrb–/– mice (n = 6 per genotype) 7 h after intravenous infection with 2 × 106 
PFU of VSV. b: Immunofluorescence assay of spleen sections from WT or Jh–/– mice or 
from WT or Tcrb–/– mice 7 h after intravenous infection with 2 × 108 PFU of VSV stained 
with VSV glycoprotein (green) and CD169 (red). One of six representative slides is shown. 
c: Spleen VSV titers from WT or Aid–/– mice or from WT or sIgM–/– mice (n = 6 per 
genotype) 7 h after intravenous infection with 2 × 106 PFU of VSV. Scale bars, 300 µm. 
***P < 0.001 (Student’s t-test); ns = not significant. Data are representative of two (a & c) 
experiments. One representative slide of six (b) slides is shown (mean ± SEM, a, c). 
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 3.8.17 Supplementary Figure 10: Deficient marginal zone in Ceacam1–/– mice  
   limits antiviral innate immune response 
a: Immunofluorescence of spleen sections from wild-type (WT) or Ceacam1–/– mice 
7 h after intravenous infection with 2 × 108 PFU of vesicular stomatitis virus (VSV), stained 
for VSV glycoprotein (green), CD169 (red), and B220 (blue) (n = 6 per genotype). One of 
six representative slides is shown. Scale bar, 300 µm. b: Spleen VSV titers from WT or 
Ceacam1–/– mice 7 h after intravenous infection with 2 × 106 PFU of VSV (n = 6 per 
genotype). **P < 0.01 (Student’s t-test). Data are representative of two (b), or one of two (a) 
experiments (mean ± SEM, b). 
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Figure 3-1: CEACAM1 is expressed on murine B-cell subsets. 
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Figure 3-2: CEACAM1 in B cells induces survival genes via Syk and Erk and NF-κB. 
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Figure 3-3: CEACAM1 promotes survival of B cells in vitro. 
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Figure 3-4: CEACAM1 promotes B-cell survival in vivo. 
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Figure 3-5: CEACAM1 ensures mouse survival during VSV challenge. 
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Figure 3-6: CEACAM1 facilitates LCMV-dependent B-cell activation. 
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Figure 3-7: Human B-cell subpopulations express CEACAM1. 
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Supplementary Figure 3-1: Erythrocytes stain negative for CEACAM1 
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Supplementary Figure 3-2:  CEACAM1 interacts with Syk 
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Supplementary Figure 3-3: Uncropped western blots shown in Figure 2. 
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Supplementary Figure 3-4: CEACAM1 expression affects B1a B-cell proportion in 
peritoneum 
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Supplementary Figure 3-5: BAFF receptor signaling resembles CEACAM1-mediated 
signalling 
 
 
  98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3-6: CEACAM1 influences the levels of serum immunoglobulins 
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Supplementary Figure 3-7: CEACAM1 is essential for anti-VSV-specific Ig production 
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Supplementary Figure 3-8: MZ and FO B cells can rescue survival in Ceacam1–/–  mice 
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Supplementary Figure 3-9: B cells but not other cell types are important for the 
replication of vesicular stomatitis virus in the spleen and the activation of adaptive 
immunity. 
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Supplementary Figure 3-10: Deficient marginal zone in Ceacam1–/– mice limits antiviral 
innate immune response 
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4.1 Abstract 
Clinically used human vaccination aims to induce specific antibodies that can 
guarantee long term protection against a pathogen. The reasons that other immune 
components often fail to induce protective immunity are still debated. Recently we found that 
enforced viral replication in secondary lymphoid organs is essential for immune activation. 
In this study we used the lymphocytic choriomeningitis virus (LCMV) to determine whether 
enforced virus replication occurs in the presence of virus-specific antibodies or virus-specific 
CD8+ T cells. We found that after systemic recall infection with LCMV-WE the presence of 
virus-specific antibodies allowed intracellular replication of virus in the marginal zone of 
spleen. In contrast, specific antibodies limited viral replication in liver, lung, and kidney. 
Upon recall infection with the persistent virus strain LCMV-Docile, viral replication in 
spleen was essential for the priming of CD8+ T cells and for viral control. In contrast to 
specific antibodies, memory CD8+ T cells inhibited viral replication in marginal zone but 
failed to protect mice from persistent viral infection. We conclude that virus-specific 
antibodies limit viral infection in peripheral organs but still allow replication of LCMV in the 
marginal zone, a mechanism that allows immune boosting during recall infection and thereby 
guarantees control of persistent virus. 
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4.2 Introduction 
Memory formation after antigen challenge is one of the most important hallmarks of 
the adaptive immune system1; it protects the host from exposure to the original or a slightly 
modified pathogen1. Because of this known memory formation, vaccination with attenuated 
pathogens has been an important tool for preventing outbreaks of severe pathogen-mediated 
diseases. In the Western world, the World Health Organization recommends approximately 
16 vaccinations2, 10 of which are antiviral.  
Although virus-specific CD8+ T cells are known to contribute to the control of viral 
infections, all recommended vaccinations are aimed at inducing antibodies against a 
pathogen3–7. For example, newly designed vaccines against HIV are intended to specifically 
activate HIV-specific CD8+ T cells8. However, to date, CD8+ T cell–mediated vaccines have 
failed to protect the host from persistent infection9. Therefore, the role of vaccine-induced 
virus-specific CD8+ T cells in long-term protection is still being debated10–12. To know in 
more detail why several vaccines produce protective antibodies but vaccines against HIV and 
HCV could not do so far. The mechanistic understanding may help to generate new vaccines 
in future. 
Lymphocytic choriomeningitis virus (LCMV) is a non-cytopathic virus with the 
ability to persist. The acute strain LCMV-WE is usually controlled within 1 or 2 weeks, 
primarily by virus-specific CD8+ T cells. The functions of B cells against LCMV are 
important for long-term control of the virus; however, CD8+ T cells are necessary for early 
control of LCMV. Infection with the LCMV-Docile strain leads to exhaustion of CD8+ T 
cells and therefore to persistence of the virus in the host13. 
Recently we found that antigen-presenting cells (CD169+ macrophages and CD11c+ 
dendritic cells) within the marginal zone specifically allow viral replication14. Enforced viral 
replication in the spleen is essential for activating the innate and adaptive immune systems15. 
It is still unknown whether enforced viral replication occurs after vaccination or after 
secondary infection and whether such replication is involved in immune boosting.  
In the study reported here we found that, after systemic recall, infection-specific 
antibodies allow intracellular replication of the virus in the marginal zone of the spleen but 
limit the replication of infectious virus in liver, lungs, and kidneys. Upon recall infection 
with the persistent virus strain LCMV-Docile, spleen-specific viral replication is associated 
with sufficient priming of CD8+ T cells and with viral control. In contrast to specific 
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antibodies, memory CD8+ T cells inhibit viral replication in the marginal zone thus fail to 
protect mice against persistent infection. 
  
4.3 Results 
 4.3.1 Replication of LCMV in the marginal zone is associated with immune  
                     activation and viral control. 
During primary viral infection, LCMV replicates in the marginal zone; this 
replication is essential for inducing adaptive immunity against the virus15. Histologic 
examination of the spleen on day 3 after infection with 2 × 104 plaque-forming units (PFU) 
of the acute strain LCMV-WE detected staining of LCMV along the marginal zone (Fig. 
1A). This finding was associated with the induction of virus-specific CD8+ T cells (Fig. 1B) 
and the induction of LCMV-specific antibodies (Fig. 1C); these activities resulted in control 
of the virus within 8 days (Fig. 1D). For early control of the virus, virus-specific CD8+ T 
cells are essential, as demonstrated by our finding that B2m−/− mice, which lack CD8+ T 
cells, could not control the virus in the circulation (Fig 1E). Jh−/− mice, which are deficient 
in B cells, controlled the virus in a manner similar to that of wild-type mice (Fig 1E); this 
finding emphasizes that early control of LCMV-WE depends primarily on virus-specific 
CD8+ T cells. Therefore, we conclude that enforced viral replication leads to the priming of 
CD8+ T cells, which are necessary for early viral control, whereas B cells are most likely 
needed for long-term protection against LCMV16,17. 
 
 4.3.2 Virus-specific antibodies, but not virus-specific CD8+ T cells, allow viral  
                     replication in the marginal zone. 
 Recall viral infections often boost the existing immune response18. Whether an 
immune-response boost after a recall infection with LCMV requires viral replication and 
whether adaptive memory components allow replication of virus in the marginal zone remain 
unknown. To gain insights into this question we first infected mice with 200 PFU of LCMV-
WE and then 50 days later challenged them with 2 × 107 PFU of LCMV-WE. We could not 
detect any replication of virus within the marginal zone after recall infection (Fig. 2A). In 
line with this finding, no infectious virus was detected in any organ tested (Fig. 2B). These 
findings suggest that memory mice are well protected against LCMV recall infection. 
 Next we aimed to determine how various specific memory immune components limit 
viral replication in the marginal zone and peripheral organs. We infected wild-type (WT) 
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mice with 2 × 106 PFU of LCMV-WE, and after 80 to 120 days of infection we transferred 
various memory components from these infected mice into naïve WT mice. For control mice 
we transferred immune components from naïve mice to naïve mice. We focused on the 
transfer of serum for virus-specific antibodies, sorted splenic B cells, splenic CD8+ T cells, 
and splenic CD4+ T cells. For each memory component we transferred approximately 20% of 
the specific compartment of an LCMV-infected mouse (see Material and Methods). Two 
days after transfer we challenged mice with 2 × 106 PFU of LCMV-WE, and at days 1, 2, and 
3 we analyzed viral distribution. Mice that received naïve immune components exhibited 
normal staining of LCMV in the marginal zone (Fig. 2C, Supplementary Figure 1A). Both 
virus-specific CD8+ T cells and antibodies allowed replication of virus at day 1 
(Supplementary Figure 1A and 1B). After day 1, virus-specific CD8+ T cells inhibited the 
replication of virus in the marginal zone (Fig. 2C, Supplementary Figure 1A). Perforin 
deficient LCMV-specific CD8+ T cells which were primed with recombinant LCMV 
(rLCMV) (see material and methods) did not effect the virus replication in marginal zone 
(Supplementary Figure 1C) suggesting that direct cytotoxicity of virus-specific CD8+ T 
cells mediated by perforin killed virus-infected antigen-presenting cells in the marginal zone 
(Supplementary Figure 1C). Transfer of virus-specific antibodies slightly reduced LCMV 
staining in the marginal zone but still allowed abundant replication at any time tested (Fig. 
2C, Supplementary Figure 1A). Transfer of memory CD4+ T cells or memory B cells 
exerted no measurable influence on the replication of LCMV in the marginal zone 
(Supplementary Fig. 2A). 
 Next we analyzed the role of virus-specific CD8+ T cells and virus-specific antibodies 
on the early distribution of virus in other organs. Virus-specific CD8+ T cells reduced 
infectious virus in the spleen and lymph node alone after day 1 (Fig. 2D and Supplementary 
Figure 1B). Interestingly, although we found limited staining of virus-infected cells in the 
marginal zone, the levels of infectious LCMV were still easily detectable. This is probably 
due to the fact that virus-specific CD8+ T cells target virus-bearing cells rather than free 
infectious virus. In peripheral organs, virus-specific CD8+ T cells exerted only a limited 
effect on viral replication (Fig. 2D and Supplementary Figure 1B). This finding suggests 
that virus-specific CD8+ T cells exert limited influence on the early replication of virus in the 
spleen, lymph nodes, liver, and lungs. 
 Like virus-specific CD8+ T cells, virus-specific antibodies reduced the amount of 
infectious virus in the spleen and lymph nodes but still allowed replication of virus (Fig. 2D, 
 
 
  111 
 
Supplementary Figure 1B). However, unlike virus-specific CD8+ T cells, virus-specific 
antibodies completely blunted the replication of virus in all peripheral organs tested (Fig. 2D, 
Supplementary Figure 1B). Memory B cells and CD4+ T cells exerted no significant effect 
on the replication of virus in any of the organs tested (Supplementary Figure 2B), a finding 
implying that memory B and CD4+ T cells have no impact on the early distribution of virus. 
Therefore, we conclude that virus-specific antibodies allow the replication of virus in the 
splenic marginal zone but protect against the replication of virus in peripheral organs. Virus-
specific CD8+ T cells inhibit the replication of virus in the marginal zone but have limited 
impact on the replication of virus in peripheral organs. 
 Next we determined whether antigen-specific CD8+ T cells that were primed with 
Listeria monocytogenes behaved in the same manner as transferred virus-specific CD8+ T 
cells. We infected WT mice with L. monocytogenes expressing the glycoprotein of LCMV 
(LM-GP33) or with wild-type L. monocytogenes (LM-WT). Mice infected with LM-GP33 
generated LCMV GP33-specific CD8+ T cells (Fig. 3A and B). After 30 days the mice were 
infected with LCMV-WE. Control mice infected with LM-WT exhibited normal replication 
of virus in the marginal zone (Fig. 3C). In contrast, mice challenged with LM-GP33 did not 
exhibit viral staining in the marginal zone (Fig. 3C), a finding indicating inhibition of virus 
in the marginal zone by virus-specific CD8+ T cells. Virus-specific CD8+ T cells generated 
after LM-GP33 infection reduced the replication of infectious virus in lymph nodes and 
lungs; however, they did not influence the replication of virus in the liver (Fig. 3D). 
 Therefore, we conclude that virus-specific antibodies allow viral replication in the 
marginal zone but suppress viral replication in other organs. Virus-specific CD8+ T cells 
suppress viral replication in the marginal zone but have limited influence on viral replication 
in peripheral organs. 
 
 4.3.3 Virus-specific antibodies allow innate and adaptive immune activation. 
 We found that virus-specific CD8+ T cells and virus-specific antibodies exert 
different effects on early viral distribution. Next we examined how differences in viral 
replication affect innate and adaptive immune activation. We transferred virus-specific 
antibodies or CD8+ T cells from memory mice into naïve C57BL/6 mice and infected them 
with LCMV-WE. Virus-specific CD8+ T cells strongly reduced the induction of antiviral 
interferon type I (IFN-I) (Fig. 4A). The presence of virus-specific antibodies also reduced the 
IFN-I response (Fig. 4A) but to a lower extent than did virus-specific CD8+ T cells (Fig. 4A).
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 Next we examined the antiviral CD8+ T cell response after LCMV infection. Transfer 
of virus-specific CD8+ T cells before infection exerted no effect on the total number of virus-
specific CD8+ T cells at day 10 after challenge with LCMV-WE (Fig. 4B upper panel, 4C). 
Non-transferred endogenous virus-specific CD8+ T cells exhibited reduced activation in the 
presence of memory CD8+ T cells (Supplementary Figure 3). In contrast, in the presence of 
virus-specific antibodies the expansion of virus-specific CD8+ T cells was greater than that in 
mice receiving virus-specific CD8+ T cells or in mice receiving non-specific immune 
components (Fig. 4B upper panel and 4C). In addition, the production of IFN-γ after in vitro 
restimulation was enhanced in splenocytes derived from mice treated with virus-specific 
antibodies (Fig. 4B middle panel and 4D). The total number of IFN-γ –producing CD4+ T 
cells was also enhanced in the spleens of mice that had received virus-specific antibodies 
(Fig. 4B lower panel and 4E). 
 We conclude that virus-specific antibodies allow innate immune activation and exert 
a positive effect on the induction of virus-specific CD8+ T cells. In contrast, the presence of 
virus-specific CD8+ T cells is not beneficial for immune activation upon challenge infection.  
 
4.3.4 Virus-specific antibodies protect against immunopathology and lead to  
                     control of virus. 
Next we investigated the influence of virus-specific CD8+ T cells or virus-specific 
antibodies on overall outcome after infection with the persistent LCMV-Docile strain. Unlike 
LCMV-WE, LCMV-Docile induces persistent viral infection (Supplementary Figure 4A). 
We transferred virus-specific CD8+ T cells and virus-specific antibodies to naïve mice and 
infected them with 2 × 104 PFU of LCMV-Docile. As was true of challenge infection with 
the acute LCMV-WE strain, the presence of virus-specific antibodies allowed viral 
replication, and virus-specific CD8+ T cells almost inhibited viral replication in the splenic 
marginal zone (Fig. 5A). Unlike virus-specific CD8+ T cells, virus-specific antibodies totally 
blunted viral load in the peripheral organs (Supplementary Figure 4B). Transfer of virus-
specific antibodies enhanced the priming and expansion of virus-specific CD8+ T cells (Fig. 
5B). But transfer of virus-specific CD8+ T cells before infection abrogated the expansion of 
antigen specific CD8+ T cells (Fig. 5B). In line with these findings, our study showed that 
mice that received virus-specific antibodies before infection could eliminate LCMV-Docile, 
whereas it persisted in mice transferred with naïve immune components and in mice treated 
with virus-specific CD8+ T cells (Fig. 5C). Virus-specific antibodies prevented elevation of 
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serum alanine aminotransaminase (ALT) and lactate dehydrogenase (LDH) activity, which 
are signs of virus-induced immunopathology (Fig. 5D). Interestingly, the transfer of virus-
specific CD8+ T cells reduced immunopathology, a finding that is in line with reduced 
activation of CD8+ T cells. Next we subjected mice that had been vaccinated with LM-GP33 
to infection with LCMV-Docile. As in our transfer experiments, LM-GP33–vaccinated mice 
could not eliminate LCMV-Docile (Fig. 5E).  
Next we examined whether the priming of CD8+ T cells in the presence of virus-
specific antibodies was essential for the control of LCMV-Docile. We transferred virus-
specific antibodies into B2m−/− mice, which lack CD8+ T cells. In the absence of CD8+ T 
cells, virus-specific antibodies did not control LCMV-Docile infection (Fig. 5F), a finding 
suggesting that secondary CD8+ T-cell activation is essential for viral control after challenge 
infection. 
 
4.3.5 Virus-specific antibodies enhance priming and expansion of CD8+ T cells. 
We found that the priming and expansion of virus-specific CD8+ T cells was highly 
improved in the presence of virus-specific antibodies. Virus-specific antibodies, which were 
used for the transferred experiments showed only slight neutralization capacity in in-vitro 
assay (Fig. 6A). To gain insights into the mechanism of action of virus-specific antibodies, 
we first determined whether these antibodies simply reduced the amount of free infectious 
virus immediately after infection. To do so, we examined CD8+ T-cell activation after 
infection with various doses of LCMV-Docile with or without additional treatment with 
LCMV-specific antibodies (LCMV-Ab). Viral control was possible after infection with 200 
PFU, 1000 PFU, or 20,000 PFU in the presence of virus-specific antibodies (Fig. 6B). In the 
absence of these antibodies, maximal CD8+ T-cell priming was achieved with an infectious 
dose of 200 PFU LCMV-Docile (Fig. 6C, D and E). In the presence of virus-specific 
antibodies the priming of CD8+ T cells was even higher than after infection of 200 PFU (Fig. 
6D and E), a finding suggesting that additional mechanisms other than reducing the 
infectious dose contribute to enhancements in the priming of CD8+ T cells. 
 
 4.3.6 Immune activation in the presence of virus-specific antibodies is essential  
                     for controlling persistent infection. 
 We found that the transfer of virus-specific antibodies leads to strong priming of 
CD8+ T cells, which is associated with viral control and limited immunopathology. Recently 
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we found that the IFN-I inhibitor Usp18 is highly expressed in CD169+ marginal zone 
macrophages and dendritic cells and is therefore crucial for viral replication in these cells 
reside in spleen and lymph nodes14,15. The absence of either marginal zone macrophages or 
Usp18 limits viral replication, and this limitation is associated with the absence of antiviral 
innate or adaptive immune responses14,15. To determine whether Usp18-dependent viral 
replication in marginal zone macrophages is also necessary for the activation of CD8+ T cells 
after secondary antigen challenge, we next transferred virus-specific antibodies to WT and 
CD169-DTR mice, in which specific CD169+ marginal zone macrophages can be depleted by 
injecting diphtheria toxin, and infected them with LCMV-Docile. In the absence of marginal 
zone macrophages, virus-specific CD8+ T-cell expansion (Fig. 7A) and IFN-γ production by 
CD8+ T cells (Fig. 7B) and CD4+ T cells (Fig. 7C) were reduced. This lack of a sufficient 
virus-specific CD8+ T-cell response leads to viral persistence (Fig. 7D). 
 Furthermore, to examine the role of Usp18 we transferred virus-specific antibodies to 
WT and Usp18−/− mice and infected the mice with LCMV-Docile. In absence of Usp18, viral 
replication was impaired in splenic marginal zone macrophages (Fig. 8A and supplementary 
Figure 5). The absence of Usp18 limited the expansion of virus-specific CD8+ T cells (Fig. 
8B) and reduced IFN-γ production by CD8+ T cells (Fig. 8C) and CD4+ T cells (Fig. 8D). 
The lack of innate and adaptive immune activation in the absence of Usp18 was associated 
with a problem in viral clearance (Fig. 8E). This finding suggests that, in the presence of 
virus-specific antibodies, Usp18 is necessary for viral replication in marginal zone 
macrophages and also enhances the priming of virus-specific CD8+ T cells. 
 
4.4  Discussion 
In the study reported here, we found that virus-specific antibodies limit the quantity 
of infectious virus in peripheral organs but still allow viral replication in the marginal zone. 
This specific distribution of virus after challenge with infection is beneficial for innate and 
adaptive immune activation; it limits immunopathology and leads to viral control. 
Currently the World Health Organization (WHO) recommends 10 antiviral 
vaccinations, which clearly protect the vaccinated host from infection with the live pathogen. 
Natural viral infection induces plasma cells, which produce virus-specific antibodies19. 
Although specific antibodies mainly target infectious virus particles, virus-specific CD8+ T 
cells can directly suppress viral replication in infected cells20. Currently available 
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vaccinations induce measurable antibodies against the pathogen but often fail to induce virus-
specific CD8+ T cells21. Some reports suggest that, after secondary infection or vaccination, 
contact with the virus will further activate the immune system, which then induces protective 
T-cell immunity22–24. Indeed, in the Friend virus model, antibodies can enhance the virus-
specific CD8+ T-cell response25. The results of our study show that specific antibodies block 
viral replication within peripheral organs within the first days after infection but still allow 
enforced viral replication in lymphoid organs. We found that the presence of antibodies 
limited viral replication in the liver and induced more-efficient antiviral CD8 T cells. The 
organ-specific antiviral capacity of virus-specific antibodies may be due to differential 
expression of Fc receptors in different organs. One way to induce such antiviral mechanisms 
could be via Fc receptor III (CD16), which either tracks virus into various vesicular 
compartments or induces antiviral activity26. In addition, complement may track virus into a 
separate compartment27. Further studies remain to be done to analyse the mechanism of Fc 
receptors on antiviral activity in macrophages. The production of antiviral cytokines and 
virus-specific CD8+ T cells could be induced and could lead to rapid control of recall 
infection. Therefore, we suggest that antibodies are, at least for some viruses, much more 
potent memory components than are CD8+ T cells. 
Immunological memory against hepatitis C virus (HCV) is a challenge to the immune 
system, and the generation of vaccines against HCV has failed to date28. One reason for this 
failure is that the virus can mutate quickly during infection; when this happens, the existing 
immunological memory is no longer protective29. On the basis of our findings, we suggest 
that a good vaccine should still allow some viral replication in certain secondary lymphoid 
niches but should also inhibit the spread of virus to the susceptible organ. We suggest that, 
because HCV replication in antigen-presenting cells is very limited or almost absent, it is 
probably impossible for CD8+ T cells to be primed in the presence of virus-specific 
antibodies. This hypothesis may at least partially explain the failure of HCV vaccines. 
Recently it was shown that preexposure to HCV antigen induces the production of CD8+ T 
cells, which suppress the immune response after viremic infection with HCV30. Although the 
authors of that study explained this phenomenon by the presence of regulatory T cells, it is 
possible that rapid inhibition of viral replication may limit the draining of HCV antigen to 
secondary lymphoid organs and can thereby limit the induction of a protective antiviral 
immune response. 
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Of course, we may question whether the mechanisms we found for LCMV are also 
relevant to HIV. HIV-specific antibodies do not induce protective immunity31, and cellular 
immunity does not lead to a protective immune response upon challenge infection32. The fact 
that HIV induces marginal zone atrophy and marginal zone lymphoma33,34 and the fact that 
CD4+ T cells can be activated in the marginal zone and are the main target cells of HIV 
infection14 suggest that the marginal zone is a niche in which activated CD4+ T cells are 
easily infected. In light of our findings, we suggest that allowing HIV replication in the 
marginal zone of the spleen may in this special case be a disadvantage, because activated 
CD4+ T cells are located mainly within the marginal zone. Although this hypothesis could 
explain the difficulties in generating an HIV vaccine31, the generation of more data from HIV 
animal models is necessary before we can draw conclusions about the relationship between 
antibodies, CD8+ T cells, and HIV replication in the marginal zone. 
 In conclusion, we found that specific antibodies are much more potent than CD8+ T 
cells in protecting mice against viruses that are prone to persistence because these antibodies 
blunt the replication of virus in peripheral organs but allow replication of virus in the 
marginal zone, thereby leading to effective immune priming. 
 
4.5 Methods 
 4.5.1 Mice. 
CD169-DTR, Jh−/−, Prf1−/−, and B2m−/− mice were maintained on a C57BL/6 background. 
CD45.1 congenic mice were used as wild type mice to track the cells. Usp18−/− mice were 
maintained on a mixed background, and mice were directly compared to littermate controls. 
KL25 mice, which express the immunoglobulin heavy chain of LCMV-neutralizing 
antibodies were maintained on a CD45.1 background and serum of LCMV infected KL25 
mice was used as positive control for in vitro virus neutralization assay. This study was 
approved by the Nordrhein Westfalen Landesamt für Natur, Umwelt und Verbraucherschutz 
(Recklinghausen, Germany) and carried out in accordance with the German law for animal 
protection. All the experimental protocols were approved by the Nordrhein Westfalen 
Landesamt für Natur, Umwelt und Verbraucherschutz (Recklinghausen, Germany) or with 
the institutional guidelines of the Ontario Cancer Institute of the University Health Network 
and at McGill University. 
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 4.5.2 Pathogens and plaque assays. 
The LCMV-WE and LCMV-Docile strains were originally obtained from F. Lehmann-Grube 
(Heinrich Pette Institute, Hamburg, Germany) and were propagated on L929 cells, MC57 
cells, or both. Mice were infected intravenously with various doses of LCMV. LCMV viral 
titers were detected by plaque-forming assays on MC57 fibroblasts, as previously 
described35. A replication-deficient recombinant LCMV (rLCMV; kindly provided by 
Pinschewer) that express the mutated form of LCMV-GP but still has antigenic properties 
was produced according to standard protocols36 and was injected intravenously into mice. 
The recombinant Listeria monocytogenes expressing the epitope of glycoprotein 33–41 of 
LCMV (LM-GP33) and wild-type Listeria monocytogenes (LM-WT) were grown in brain-
heart infusion medium diluted in phosphate buffered saline (PBS) and were injected 
intravenously into mice. 
 
 4.5.3 Memory cells and immune serum isolation and transfer. 
Six- to 8-week-old C57BL/6 naïve mice were infected intravenously with 2 × 106 PFU of 
LCMV-WE. After 80 to 120 days of infection, immune components were isolated from these 
memory mice. LCMV-immune serum was collected and pooled from a group of mice, and 
virus-free serum was used to inject intravenously into mice for all experiments. CD8+ T cells, 
CD4+ T cells, and B220+ cells were isolated from spleen of memory mice with magnetic-
activated cell sorting (MACS) isolation kit, according to the manufacturer’s protocol 
(Miltenyi Biotec, Germany). Serum and memory-cell transfers were performed 2 days before 
the infection. Mice were injected once intravenously with 300 μl of immune serum, 5 × 106 
memory CD8+ T cells, 1 × 107 memory CD4+ T cells, or 1 × 107 memory B cells. Prf1−/− 
mice were infected with 2 × 105 PFU of rLCMV and for control group C57BL/6 naïve mice 
got 2 × 105 PFU of rLCMV infection. After 30 days spleens of these memory mice were used 
as donors for LCMV-specific memory CD8+ T cells. 
 
 4.5.4 Histologic analysis. 
Histologic analyses of snap-frozen tissues were performed with mouse monoclonal 
antibodies to LCMV nucleoprotein (NP; made in house), CD169 (MCA884F; AbD Serotec, 
Germany), or CD45R/B220 (RA3-6B2; eBioscience, Germany). Red pulp macrophages were 
stained with F4/80 (BM8; eBiosciences). 
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4.5.5 Enzyme-linked immunosorbent assays. 
Interferon-alpha (IFN-α) enzyme-linked immunosorbent assays (ELISA) were performed 
according to the manufacturer’s protocol (PBL Interferon Science, Germany). 
 
4.5.6 Flow cytometry. 
The Tetramer Facility of National Institutes of Health (NIH) provided LCMV-GP33 
tetramer. Cells were stained with allophycocyanin (APC)-labeled GP33 MHC class I 
tetramer (GP33/H-2Db) for 15 minutes at 37 °C. After incubation, the samples were stained 
with anti-CD8 (clone 53–6.7; eBioscience) or anti-CD4 (clone GK1.5; eBioscience) 
antibodies for 30 minutes at 4 °C. Absolute numbers of GP33-specific CD8+ T cells were 
calculated with fluorescent beads (BD Biosciences) by using fluorescence-activated cell 
sorting (FACS). For measurement of intracellular IFN-γ, cells were fixed with 2% 
formaldehyde in PBS for 10 minutes, permeabilized with 1% saponin in FACS buffer at 
room temperature, and stained with anti–IFN-γ antibody for 30 minutes at 4 °C (clone 
XMG1.2; eBioscience). All stained cells were analysed with a FACS Fortessa (BD 
Biosciences) flow cytometer, and data were analysed with FlowJo software. 
 
 4.5.7 ALT and LDH measurement. 
The activity of ALT and LDH was measured in the Central Laboratory, University Hospital 
Essen, Germany. 
 
 4.5.8 LCMV neutralization assay. 
The neutralizing capability of serum was measured with plaque-forming assays according to 
a previously published protocol35. 
 
 4.5.9 Statistical analysis. 
Data are expressed as means ± SEM. Student’s t-test was used to detect statistically 
significant differences between groups. Significant differences between several groups were 
detected by one-way analysis of variance (ANOVA) with the Bonferroni or Dunnett post hoc 
test. The level of statistical significance was set at P < 0.05. 
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4.8 Figure Legend 
 4.8.1 Figure 1: Replication of lymphocytic choriomeningitis virus (LCMV) in the  
                     marginal zone is associated with immune activation and viral control  
C57BL/6 mice were infected intravenously with 2 × 104 plaque-forming units (PFU) of 
LCMV strain WE (LCMV-WE) and were analysed for various parameters. (A) 
Representative immunofluorescence of spleen after 3 days of infection, stained for LCMV 
nucleoprotein (red), marginal zone macrophages (CD169, green), and red pulp macrophages 
(F4/80, blue). One slide representative of 6 slides is shown. Scale bar, 200 μm. (B) Total 
number of LCMV-specific T cells in the blood that were positive for the MHC class I 
tetramer of the glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+), as measured by 
fluorescence activated cell sorting (FACS) at the indicated days after infection (n = 3–7). (C) 
LCMV GP-specific antibodies in serum were analysed by enzyme-linked immunosorbent 
assay (ELISA) on various days after infection (n = 4). (D) Viral titers from spleen and 
inguinal lymph nodes were analysed by plaque-forming assay at the indicated time points 
after infection (n = 3). (E) Viral titers in serum of wild type (WT), B2m−/−, and Jh−/− mice on 
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various days after infection (n = 4). Horizontal dotted lines designate the detection limit. Data 
are shown as mean ± SEM. 
 
 4.8.2 Figure 2: Virus-specific antibodies, but not virus-specific CD8+ T cells,  
                     allow viral replication in the marginal zone. 
(A) Naïve (non-memory) and memory C57BL/6 mice were infected intravenously with 2 × 
107 plaque-forming units (PFU) of lymphocytic choriomeningitis virus strain WE (LCMV-
WE). After day 1 spleen sections were stained for LCMV nucleoprotein (red), marginal zone 
macrophages (CD169, green), and red pulp macrophages (F4/80, blue). One slide 
representative of 4 slides is shown. Scale bar, 100 μm. (B) Viral titers from spleen, inguinal 
lymph nodes (LN), liver, and lungs of naïve and memory C57BL/6 mice infected 
intravenously with 2 × 107 PFU of LCMV-WE, as measured on day 1 (n = 4–6). (C, D) 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with LCMV-specific CD8+ T cells 
and LCMV-specific antibodies (immune serum) collected from memory mice. After 2 days 
all mice were infected with 2 × 106 PFU of LCMV-WE. (C) Representative 
immunofluorescence of spleen after 3 days of viral infection, stained for LCMV 
nucleoprotein (red) and marginal zone macrophages (CD169, green). One slide 
representative of 6 slides is shown. Scale bar, 200 μm. (D) Viral titers from spleen, inguinal 
lymph node (LN), liver, and lungs after 3 days of viral infection (n = 6–7). Horizontal dotted 
lines designate the detection limit. Data are shown as mean ± SEM and are pooled from 2 or 
3 independent experiments. 
 
 4.8.3 Figure 3: Inhibition of viral replication in splenic marginal zone of mice 
primed with recombinant Listeria monocytogenes expressing the glycoprotein of LCMV 
C57BL/6 naïve mice were infected with 1 × 106 colony-forming units (CFU) of Listeria 
monocytogenes expressing the glycoprotein of lymphocytic choriomeningitis virus (LM-
GP33), and control mice were infected with a lower dose (1 × 104 CFU) of wildtype L. 
monocytogenes (LM-WT) as higher dose is lethal for mice. After 30 days mice were injected 
with 2 × 106 PFU of LCMV-WE. (A) Fluorescence-activated cell sorting (FACS) plots 
showing the frequency of T cells that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in the total number of CD8+ T cells 
in the blood at indicated days after LM-GP33 infection. (B) Graph showing the total number 
of Tet-GP33+ CD8+ T cells in blood on various days after LM-GP33 infection (n = 6). (C) 
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Immunohistochemical analysis of spleens from LM-GP33–primed mice after 3 days of 
LCMV strain WE (LCMV-WE) infection, showing LCMV nucleoprotein (red) and marginal 
zone macrophages (CD169, green). Scale bar, 200 μm (n = 5). (D) Viral titers from spleen, 
inguinal LN, liver, and lungs after 3 days of LCMV-WE infection (n = 5). Horizontal dotted 
lines designate the detection limit. Data are shown as mean ± SEM and are pooled from 2 
independent experiments. 
 
4.8.4 Figure 4. Virus-specific antibodies allow innate and adaptive immune  
                     activation 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with lymphocytic choriomeningitis 
(LCMV)-specific CD8+ T cells and LCMV-specific antibodies (immune serum) collected 
from memory mice. After 2 days all mice were infected with 2 × 106 plaque-forming units 
(PFU) of LCMV strain WE (LCMV-WE). (A) Levels of interferon (IFN)-α were measured in 
the serum by enzyme-linked immunosorbent assay (ELISA) after 2 days of infection (n = 6). 
(B) Representative fluorescence-activated cell sorting (FACS) plots showing the frequency 
of LCMV-specific T cells in the spleen that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in the total number of CD8+ T cells 
in the spleen (upper plots). Frequency of IFN-γ+ CD8+ T cells (middle plots) and IFN-γ+ 
CD4+ T cells (lower plots) in the spleen after in vitro stimulation with LCMV GP33 and 
LCMV GP64 peptide respectively after 10 days of viral infection. (C) Total number of 
LCMV-specific Tet-GP33+ CD8+ T cells in the spleen after 10 days of viral infection (n = 4–
6). (D) Total number of IFN-γ+ CD8+ T cells in the spleen after 10 days of viral infection and 
after in vitro stimulation with LCMV GP33 peptide for 5 hours (n = 4–6). (E) Total number 
of IFN-γ–producing CD4+ T cells in the spleen after 10 days of viral infection and after in 
vitro stimulation with LCMV GP64 peptide for 5 hours (n = 3–6). Data are shown as mean ± 
SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 
0.001 (Student’s t-test). 
 
4.8.5 Figure 5. Virus-specific antibodies protect against immunopathology and  
                     lead to control of virus 
C57BL/6 naïve mice were injected separately with naïve CD8+ T cells and non-specific 
antibodies (naïve serum) collected from naïve mice, and with lymphocytic choriomeningitis 
virus (LCMV)-specific CD8+ T cells and LCMV-specific antibodies (immune serum) 
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collected from memory mice. After 2 days all mice were infected with 2 × 104 plaque 
forming units (PFU) of LCMV-Docile. (A) Representative immunofluorescence of spleen 
after 3 days of infection, stained for LCMV nucleoprotein (red) and marginal zone 
macrophages (CD169, green). One slide representative of 3 slides is shown. Scale bar, 200 
μm. (B) Total number of LCMV-specific T cells in the spleen that were positive for the MHC 
class I tetramer of the glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) after 10 days 
of viral infection (n = 4–7). (C) Viral titers from spleen, inguinal LN, liver, kidney, and lungs 
after 10 days of viral infection (n = 7–10). (D) Levels of alanine aminotransaminase (ALT) 
and lactate dehydrogenase (LDH) in serum were measured after 10 days of viral infection (n 
= 7–10). (E) C57BL/6 mice primed with Listeria monocytogenes expressing the glycoprotein 
of lymphocytic choriomeningitis virus (LM-gp33) were infected with 2 × 106 PFU of 
LCMV-Docile. After 10 days viral titers were measured in various organs, as indicated (n = 
5–8). (F) C57BL/6 and B2m−/− mice were treated with virus-specific antibodies or were left 
untreated. After 2 days all mice were infected with 2 × 104 PFU of LCMV-Docile. Viral 
titers from spleen, inguinal LN, liver, kidney, and lungs were measured after 10 days of viral 
infection (n = 3–4). Horizontal dotted lines designate the detection limit. Data are shown as 
mean ± SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001 (Student’s t-test). 
 
4.8.6 Figure 6: Virus-specific antibodies enhance priming and expansion of  
                       CD8+ T cells. 
(A) Graph showing the total neutralizing antibodies in naïve serum (WT, naive), serum from 
memory C57BL/6 mice (WT, LCMV) on day 100 and from KL25 mice (KL25, LCMV) on 
day 10 after infection with 2 × 106 PFU of LCMV-WE and determined by in vitro 
neutralization assay (n = 4–5). (B–E) Naïve C57BL/6 mice were injected with non-specific 
antibodies or LCMV-specific antibodies. Mice treated with non-specific antibodies were 
infected separately with 2 × 102, 1 × 103, 5 × 103, or 2 × 104 PFU of LCMV-Docile. Mice 
treated with LCMV-specific antibodies were infected with 2 × 104 PFU of LCMV-Docile. 
(B) Viral titers in various organs after 10 days of viral infection (n = 6). (C) FACS plots 
representing the frequency of LCMV-specific Tet-GP33+ CD8+ T cells in blood (upper plots) 
and spleen (middle plots) after 10 days of infection. Lower plots show the frequency of 
interferon (IFN)-γ+ CD8+ T cells in spleen after 10 days of viral infection and in vitro 
stimulation with LCMV GP33 peptide (n = 6–9). (D) Total number of LCMV-specific Tet-
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GP33+ CD8+ T cells in spleen after 10 days of viral infection (n = 6–9). (E) Total number of 
IFN-γ+ CD8+ T cells in spleen after in vitro stimulation with LCMV GP33 peptide on day 10 
of infection (n = 6–9). Horizontal dotted lines designate the detection limit. Data are shown 
as mean ± SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001 (Student’s t-test). 
 
 4.8.7 Figure 7: Immune activation in the presence of virus-specific antibodies is  
                   essential for controlling persistent viral infection.  
Naïve C57BL/6 mice and CD169-DTR mice were treated with diphtheria toxin (30 μg/kg) on 
day -3 and day 2 and were injected with lymphocytic choriomeningitis (LCMV)-specific 
antibodies on day -2. One group of C57BL/6 mice was injected with non-specific antibodies 
on day -2. All mice were infected with 2 × 104 plaque-forming units (PFU) of LCMV-Docile 
on day 0. Ten days later mice were evaluated for various parameters. (A) Total number of 
LCMV-specific T cells in spleen that were positive for the MHC class I tetramer of the 
glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) (n = 6). (B) Total number of 
interferon (IFN)-γ+ CD8+ T cells in spleen was determined after in vitro stimulation with or 
without LCMV GP33 peptide for 5 hours (n = 6). (C) Total number of IFN-γ producing 
CD4+ T cells in spleen after in vitro stimulation with or without LCMV GP64 peptide for 5 
hours (n = 6). (D) Viral titers in spleen, inguinal lymph nodes (LN), liver, kidney, and lungs 
were measured after 10 days of viral infection (n = 6). Data are shown as mean ± SEM and 
are pooled from 2 independent experiments. *P < 0.05; **P < 0.01 and ***P < 0.001 
(Student’s t-test). 
 
4.8.8 Figure 8: Immune activation in the presence of virus-specific antibodies is  
                     Usp18 dependent. 
Lymphocytic choriomeningitis virus (LCMV)-specific antibodies were injected into Usp18−/− 
mice and littermate control mice. Non-specific antibodies were injected into littermate 
control mice to form a control group. Mice were challenged with LCMV-Docile. (A) 
Immunohistochemical analysis of spleen showing LCMV nucleoprotein (red), marginal zone 
macrophages (CD169, green), and follicular B cells (B220, blue) after 1 day of infection with 
2 × 106 plaque-forming units (PFU) of LCMV-Docile (n = 3). Scale bar, 200 μm. (B–E) 
Mice were infected with 2 × 104 PFU of LCMV-Docile and were evaluated for various 
parameters after 10 days of infection. (B) Total number of LCMV-specific T cells in the 
spleen that were positive for the MHC class I tetramer of the glycoprotein of LCMV (Tet-
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GP33+) and for CD8 (CD8+) (n = 5–8). (C) Total number of interferon (IFN)-γ+ CD8+ T cells 
in the spleen was determined after in vitro stimulation with or without LCMV GP33 peptide 
for 5 hours (n = 5–8). (D) Total number of IFN-γ producing CD4+ T cells after in vitro 
stimulation with or without LCMV GP64 peptide for 5 hours in spleen (n = 5–8). (E) Viral 
titers from spleen, inguinal lymph nodes (LN), liver, kidneys, and lungs (n = 7–8). Data are 
shown as mean ± SEM and are pooled from 2 or 3 independent experiments. *P < 0.05; **P 
< 0.01; ***P < 0.001 (Student’s t-test). 
 
4.8.9 Supplementary Figure 1: Virus‐specific antibodies, but not virus‐specific  
                     CD8+ T cells, allow viral replication in the marginal zone. 
(A, B) C57BL/6 naïve mice were injected with naïve CD8+ T cells, non‐specific antibodies 
(naïve serum), lymphocytic choriomeningitis (LCMV)‐ specific CD8+ T cells, or 
LCMV‐specific antibodies (immune serum). After 2 days all mice were infected with 2×106 
plaque‐forming units (PFU) of LCMV strain WE (LCMV‐WE). (A) Representative 
immunofluorescence of spleen is shown after day 1 and 2 of infection, stained for LCMV 
nucleoprotein (red) and marginal zone macrophages (CD169, green). One slide 
representative of 3 slides is shown. (B) Viral titers from spleen, inguinal lymph nodes (LN), 
liver, and lungs after 1 or 2 days of viral infection (n = 3). (C,D) Memory CD8+ T cells 
isolated from C57BL/6 memory and prf1–/– memory mice were injected to CD45.1 
(wild‐type; WT) naïve mice. One CD45.1 (wild‐type; WT) group received naïve CD8+ T 
cells as control. After 2 days mice were injected with 2×104 PFU of LCMV‐WE. (C) 
Representative immunofluorescence of the spleen is shown after 3 days of infection, stained 
for LCMV nucleoprotein (red), marginal zone macrophages (CD169, green) and transferred 
CD8+ T cells (CD45.1, blue). One slide representative of 3 experiments is shown. (D) Graph 
shows the viral titers in the spleen after 3 days of infection. Horizontal dotted lines designate 
the detection limit. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P<0.001 
(Student’s t‐test). 
 
4.8.10 Supplementary Figure 2: Memory CD4+ T cells and memory B cells has no  
                     effect on viral replication in the marginal zone. 
C57BL/6 naïve mice were injected with memory B220+ B cells and memory CD4+ T cells 
isolated from memory mice. One group of mice was left untreated. After 2 days all mice 
were infected with 2×106 plaque‐forming units (PFU) of lymphocytic choriomeningitis virus 
strain WE (LCMVWE). (A) Representative immunofluorescence in spleen after 3 days of 
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infection, stained for LCMV nucleoprotein (red), marginal zone macrophages (CD169, 
green), and red pulp macrophages (F4/80, blue). One representative slide of 3 is shown. (B) 
Viral titers from various organs after 3 days of viral infection (n = 3). Horizontal dotted lines 
designate the detection limit. Data are shown as mean ± SEM.  
 
4.8.11 Supplementary Figure 3: Memory CD8+ T cells reduce the expansion of  
                     endogenous CD8+ T cells. 
CD45.1 (wild‐type; WT) congenic naïve mice were injected with lymphocytic 
choriomeningitis virus (LCMV)‐specific CD8+ T cells isolated from C57BL/6 memory mice. 
One group of mice was injected with naïve CD8+ T cells isolated from naïve C57BL/6 mice. 
After 2 days all mice were infected with 2×106 plaque‐forming units (PFU) of LCMV strain 
WE (LCMV‐WE). Total numbers of endogenous and exogenous T cells positive for the 
MHC class I tetramer of the glycoprotein of LCMV (Tet‐GP33+) and for CD8 (CD8+) in the 
spleen were determined after 10 days of infection (n = 3‐4). Data are shown as mean ± SEM. 
*P < 0.05 (Student’s t‐test). 
 
 4.8.12 Supplementary Figure 4: Virus‐specific antibodies inhibit persistent  
                     LCMV‐Docile replication in peripheral organs. 
(A) C57BL/6 naïve mice were infected separately with 2×104 plaque‐forming units (PFU) of 
lymphocytic choriomeningitis virus strain WE (LCMVWE) and LCMV‐Docile. Graph shows 
viral titers in serum on indicated days. (B) C57BL/6 naïve mice were injected with naïve 
CD8+ T cells, nonspecific antibodies (naïve serum), LCMV‐specific CD8+ T cells, or 
LCMV‐specific antibodies (immune serum). After 2 days all mice were infected with 2×104 
PFU of LCMV‐Docile. Graph shows viral titers in spleen, inguinal lymph nodes, liver, and 
lungs after 3 days of infection. Horizontal dotted lines designate the detection limit. Data are 
shown as mean ± SEM. 
 
4.8.13 Supplementary Figure 5: Usp18 promotes LCMV replication. 
Usp18–/– mice and littermate control naïve mice (wild‐type; WT) were infected with 2×106 
plaque‐forming units (PFU) of lymphocytic choriomeningitis strain Docile (LCMV‐Docile). 
Graph shows viral titers in spleen after 1 day of infection (n = 4). Horizontal dotted lines 
designate the detection limit. Data are shown as mean ± SEM. ***P < 0.001 (Student’s 
t‐test). 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Replication of lymphocytic choriomeningitis virus (LCMV) in the marginal 
one is associated with immune activation and viral control. 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: Virus-specific antibodies, but not virus-specific CD8+ T cells, allow viral 
replication in the marginal zone. 
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Figure 3 
 
 
 
 
 
 
 
 
Figure 4-3: Inhibition of viral replication in splenic marginal zone of mice primed with 
recombinant Listeria monocytogenes expressing the glycoprotein of LCMV. 
 
 
 
  129 
 
Figure 4 
 
Figure 4-4. Virus-specific antibodies allow innate and adaptive immune activation. 
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Figure 5 
 
Figure 4-5: Virus-specific antibodies protect against immunopathology and lead to control 
of virus. 
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Figure 6 
 
Figure 4-6: Virus-specific antibodies enhance priming and expansion of CD8+ T cells. 
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Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Immune activation in the presence of virus-specific antibodies is essential for 
controlling persistent viral infection. 
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Figure 8 
 
Figure 4-8: Immune activation in the presence of virus-specific antibodies is Usp18 
dependent. 
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Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4-1: Virus‐specific antibodies, but not virus‐specific CD8+ T cells, 
allow viral replication in the marginal zone. 
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Supplementary Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4-2: Memory CD4+ T cells and memory B cells has no effect on 
viral replication in the marginal zone. 
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Supplementary Figure 3 
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Supplementary Figure 4-3: Memory CD8+ T cells reduce the expansion of endogenous 
CD8+ T cells. 
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Supplementary Figure 4 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4-4: Virus-specific antibodies inhibit persistent LCMV-Docile 
replication in peripheral organs. 
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Supplementary Figure 5 
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Supplementary Figure 4-5: Usp18 promotes LCMV replication. 
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5. Chapter V: 
General Discussion and Conclusions 
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Using three different studies, we show in this thesis the role of lymphotoxin beta, 
CEACAM1 and virus specific antibodies in innate and adaptive immune activation. 
Lymphotoxin plays a major role in a variety of immunological processes including 
lymph node development, generation and activation of DC’s, B cell development, IFN-α 
production and CD169+ macrophage function.1, 2, 3 In the first part of this thesis we 
investigated different functions of Usp18 and lymphotoxin beta during viral replication in 
spleen. In a recent study, it was shown that enforced viral replication in marginal zone 
(CD169+) macrophages is essential for the generation of sufficient antigen particles to trigger 
enough IFN-α production which in turn activates the adaptive immune responses.4  CD169+ 
macrophages have higher Usp18 expression and knockdown of Usp18 or lack of CD169 
macrophages leads to limited viral replication in spleen leading to impaired priming of 
adaptive immunity. Therefore, Usp18–/– mice lack neutralizing antibodies which in turn 
causes a higher mortality rate.4 On the other hand, LTα1β2 produced from B cells is 
necessary to maintain the subcapsular sinus (SCS) macrophage phenotype within virus 
draining lymph nodes (LNs).3, 5 Mice lacking LTα1β2 from B cells also fail to replicate VSV 
and lack sufficient type I interferon production which also leads to death of these mice.3 
Hence, expression of Usp18 and secretion of LTα1β2 is integral for protection against fatal 
neuroinvasion.4, 6 
 In this study, we delineated distinct roles for these two molecules. Usp18 and 
lymphotoxin beta both are required for viral replication in the spleen. Usp18 influences viral 
replication whereas LT beta is involved in spreading the virus along the conduits of the 
marginal zone. Usp18 is important for both systemic generation of type I interferon as well as 
CD8 T-cell priming. On the other hand, we found that LT beta is necessary only for IFN-α 
secretion but not for CD8 T-cell priming. Our results showed that after LCMV infection 
Usp18 is important for cytokine secretion from CD8 T cells whereas, LT beta does not 
influence adaptive immune system activation. We determined that B cell-derived LT beta is 
an important contributor for the viral distribution along the marginal zone. Importance of 
viral distribution might be explained by large number of viral particles can activate pDC’s. 
Also, a different composition of infected cell from adjacent non-infected cells are more likely 
to infect the pDC’s leading in to activation of strong antiviral mechanisms.  
Viral spread is an important hallmark of viral distribution in organs and T-cell 
exhaustion.7 In our study, we suggest that drugs targeting the extracellular spread of virus can 
lead to better T-cell functions by preventing the exhaustion. Hence, formulation of drugs or 
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antibiotics which allow threshold viral replication can promote CD8 T cell function and can 
result in better viral control.  
In conclusion, we have shown that viral replication in CD169+ macrophages and viral 
spread along the conduits of the marginal zone are two separate mechanism of enforced viral 
replication. Viral spread primarily affect only systemic production of type I interferon and 
viral replication is absolute for activation of innate as well as adaptive immune function after 
antigen challenge. Other factors affecting lymphotoxin beta secretion or Usp18 expression 
are still relatively unknown. The role of lymphotoxin beta in lymph node formation and B 
cell function hints to there being more factors affecting B cell survival, proliferation and 
antiviral functions. One of these molecules which we study in the second part of our study 
was CEACAM1. 
In this portion of the thesis, we demonstrate that cell intrinsic signalling of 
CEACAM1 is essential for survival and proliferation of B cells. Lack of CEACAM1 leads to 
reduced numbers of B cells and defective immune responses after antigen challenge. Previous 
studies have demonstrated that CEACAM1 influences BCR-complex mediated activation.8 
CEACAM1 triggered strong proliferation of B cells when combined with surface IgM cross 
linking in B cells without affecting class switching and similar results were obtain with 
CEACAM1-expressing fibroblasts.8 Mouse B cells express relatively high long isoform of 
CEACAM1 (CEACAM1-4L) over short isoform (CEACAM1-4s). Phosphorylation of 
ITIM’s on long cytoplasmic tail give inhibitory signals in T cells by recruiting SHP-1 and 
SHP-2.9 However, in current study we showed that CEACAM1 crosslinkage has some 
proliferative effects. Our in vitro and in vivo study suggest that CEACAM1 ligation induces 
proliferative signals and is important for survival of activated B cells. Like previous studies, 
we confirm lack of CEACAM1 induces apoptotic signals in B cells. This is in line with the 
findings which shows CEACAM1 induces apoptosis in granulocytes.10 In another other study 
CEACAM1 was shown to act as a co-inhibitory receptor for granulocyte-colony stimulating 
factor receptor (G-CSFR) which regulate granulopoiesis.11 
BCR is essential for survival of B-cells. In absence of BCR all B cells as well as 
peripheral B cells were lost. This suggests that BCR either provide constitutive or tonic 
survival signal or self-antigens recognize cognate BCR’s on immature or transitional zone B 
cells.12 As the BCR is responsible for cell survival, altering BCR signal strength should alter 
the B cell fate. Modulating Bruton’s tyrosine kinase (Btk) pathway which is downstream of 
BCR revealed that antigen stimulation is necessary for survival of FO B cell and B-1 B 
cells.13 Relative strong BCR crosslinking by auto antigens favours mature FO-B cell 
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development whereas weak BCR signal favours MZ B cell development.12 In addition to 
BCR signal, constant signal via BAFF receptor (Baffr) is the most important signal for naïve 
B cell development. 
In our study, we suggest that tonic signal via CEACAM1 strongly regulates B cell 
survival. Because CEACAM1 is its own ligand, we suggest that CEACAM1 induces positive 
survival signal on B cells and maintains the structure of the B-cell follicles. We found that 
CEACAM1 contributed to Syk phosphorylation after challenge with monoclonal anti-
CEACAM1 antibody indicating that CEACAM1 is involved in the BCR complex. Unlike Jh–
/–, Baffr–/– mice, Ceacam1–/– mice showed similar reduction in B cell numbers particularly no 
MZ B-cell development in naïve mice. Similar to Ceacam1–/– mice, mice deficient in CD19 
or BCR exhibit reduced number of B cells which can be linked to humans lacking the 
Wiskott-Aldrich syndrome protein (WASp)14, which is also reported to involve in Btk 
phosphorylation15 and MZ B-cell generation16. Reduced B cell numbers particularly MZ B-
cells couldn’t give early immune activation after VSV challenge as Ceacam1–/– mice lack 
enforced viral replication in CD169+ macrophages and failed to generate adaptive immune 
response in terms of neutralizing antibodies. Insufficient antibody generation led to a breach 
of the Blood-Brain barrier and hence significant mortality rate in Ceacam1–/– mice. We also 
showed CEACAM1 expression on human peripheral B cells suggesting that CEACAM1 
could play major role in human antiviral responses. 
Reduced number of B cells leads to deficiency in antiviral antibody production. 
Antibodies play an important role in generating adaptive immune responses. Hence, in the 
third study we checked the role of virus-specific antibodies and virus specific T-cells in CD8 
T cell priming and virus control. 
Vaccination ensures the induction of specific antibodies that can generate long lasting 
protection against pathogens. Natural viral infection causes B cell activation resulting in 
plasma cell differentiation and production of virus specific antibodies.17 After vaccination or 
antigen activation B-1 cells differentiate into plasmablast generating polyspecific IgM 
antibodies which leads to the activation if CD8 and CD4 T cells. Because of CD4 T cell help 
naïve B cells become long lived plasma cell producing high number of neutralizing 
antibodies.18 
In this study, we found that upon recall infection, virus specific antibodies limit the 
viral replication in peripheral organs but still would allow replication of viral antigen in 
splenic marginal zone. This threshold replication is beneficial for innate and adaptive 
immune activation as it induces strong CD8 T cell response, limiting the immunopathology 
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leading to faster clearance of the antigen. Virus specific antibodies can target infectious 
particles, virus-specific CD8 T cells can supress viral replication and eliminate the antigen.19 
The results from our study shows that antigen specific antibodies block the antigen in 
peripheral organs but still allow viral replication in splenic marginal zone. Differential 
expression of Fc receptors in different organs may contribute to organ specific antiviral 
capacities. To generate effective memory response virus must replicate in CD169+ 
macrophages to generate functional CD8 T cell response (Fig. 5-1). Therefore, from our 
studies utilizing LCMV we can suggest that antibodies are more potent than CD8 T cells.  
 
 
 
  
 
 
  
 
 
 
 
Fig: 5-1: Long term antiviral antibody induction. (Dӧrner T, and Radbruch A, Immunity, 2007) 
 
 From our study, we can suggest that for effective vaccine treatment, vaccine should 
allow minimal viral replication in certain secondary lymphoid organs in order to generate 
adaptive immune system but also to inhibit the spread of the virus to susceptible organs. This 
could be a better vaccine strategy for HCV infection because HCV E1 and E2 envelop 
protein specific antibodies lose their neutralizing capacity due to virus escape mutations.20 
However, for HIV infections replication in marginal zone could be not beneficial because the 
activated CD4 T cells are located mainly in marginal zone and would lead to direct 
elimination of virus and could lead to immunopathology however humanised mouse model 
studies could lead us draw a conclusion for antibodies, CD8 T cells and HIV infection. 
 In conclusion, with three different studies we checked the role of different parameters 
such as lymphotoxin beta, CEACAM1 and virus specific antibodies in viral infection and 
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their influence on enforced viral replication in activating innate and adaptive immune system. 
We found that viral replication and extracellular viral spread leads to distinct outcomes in 
disease. Intracellular viral replication is important for innate and adaptive immune activation 
particularly in generating CD8 T cell responses whereas, extracellular viral spread affect type 
I interferon production. Lack of lymphotoxin beta limits the spread of virus along the 
conduits resulting in limited IFN-α production but normal CD8 T cell response. Knowing the 
role of lymphotoxin in maintaining splenic architecture especially follicular DC’s in B cell 
follicle, loss of CEACAM1 also lead to generate deficient B cell responses. CEACAM1 
expression on murine B cells is an important regulator of B cell homeostasis and maintaining 
normal B- cell numbers. CEACAM1 is essential for protective antiviral antibody generation 
and the resulting reduction in mouse mortality against cytopathic viral infection. On the other 
hand, virus specific antibodies are more potent than virus specific CD8 T cells in chronic 
viral infection because they allow viral replication in splenic marginal zone and abolish the 
replication in peripheral organs resulting in generating effective adaptive immune responses. 
In contrast to specific antibodies, memory CD8 T cells inhibited viral replication in marginal 
zone but failed to protect mice from persistent viral infection. 
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